

REVIEW

Nanoliposomes as nonviral vectors in cancer gene therapy

Safiye Nur Yildiz¹  | Maliheh Entezari^{2,3} | Mahshid Deldar Abad Paskeh^{2,3} |
 Sepideh Mirzaei⁴ | Alireza Kalbasi⁵  | Amirhossein Zabolian⁶ | Farid Hashemi⁷ |
 Kiavash Hushmandi⁸ | Mehrdad Hashemi^{2,3} | Mehdi Raei⁹ |
 Mohammad Ali Sheikh Beig Goharrizi¹⁰ | Amir Reza Aref^{11,12} | Ali Zarrabi¹³ |
 Jun Ren¹⁴ | Gorka Orive^{15,16,17,18,*} | Navid Rabiee^{19,*} | Yavuz Nuri Ertas^{1,20,21,*} 

¹Department of Biomedical Engineering, Erciyes University, Kayseri, Turkey

²Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

³Department of Medical Convergence Sciences, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

⁴Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran

⁵Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

⁶Department of Orthopedics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁷Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

⁸Department of Clinical Sciences Institute, Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

⁹Department of Epidemiology and Biostatistics, School of Health, Baqiyatallah University of Medical Sciences, Tehran, Iran

¹⁰Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran

¹¹Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

¹²Department of Translational Sciences, Xsphaera Biosciences Inc., Boston, Massachusetts, USA

¹³Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul, Turkey

¹⁴Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

¹⁵NanoBioCel Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain

¹⁶University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria-Gasteiz, Spain

¹⁷Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz, Spain

¹⁸The Academia, Singapore Eye Research Institute, Singapore, Singapore

¹⁹Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Western Australia, Australia

²⁰ERNAM—Nanotechnology Research and Application Center, Erciyes University, Kayseri, Turkey

²¹UNAM—National Nanotechnology Research Center, Bilkent University, Ankara, Turkey

*Correspondence

Gorka Orive, NanoBioCel Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain.
 Email: gorka.orive@ehu.es

Navid Rabiee, Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA 6150, Australia.

Abstract

Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off-targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Author(s). *MedComm* published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

Email: navid.rabee@murdoch.edu.au

Yavuz Nuri Ertas,
ERNAM—Nanotechnology Research and
Application Center, Erciyes University,
Kayseri, Turkey.
Email: yavuznuri@gmail.com

Funding information

Türkiye Bilimsel ve Teknolojik Araştırma
Kurumu, Grant/Award Number: 118C346

with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions.

KEYWORDS

CRISPR/Cas9, liposome, nonviral vector, shRNA, siRNA

1 | INTRODUCTION

Cancer treatment is a very challenging process that requires the application of pharmacological and genetic interventions to combat the disease. Such treatments are designed to target the underlying mechanisms of cancer cells, with the goal of inhibiting their growth and proliferation. These interventions can be delivered through a variety of approaches, including chemotherapy, radiation therapy, immunotherapy, and gene therapy. Gene therapy stands out among these methods and aims to prevent or treat various diseases by correcting or replacing mutated genes that cause specific disorders. Gene therapy has been a topic of interest since the 1960s and has made significant progress since then.¹ Gene therapy has enormous potential shortly and is poised to become a significant field in healthcare. Recent developments in molecular biology, particularly in viral vectors and genome-editing techniques, have significantly enhanced the accuracy and effectiveness of gene therapy interventions.^{2–5} This has resulted in previously incurable genetic disorders being treated with potential hope for patients and their families. However, developing safe and effective gene therapies has been challenging. Delivering gene therapy to target cells is a significant hurdle researchers must overcome. It requires a delivery system that can transport the therapeutic gene to the target cells without causing any adverse effects. Additionally, the potential for off-target effects and the risk of immunogenicity must be considered carefully. Despite these challenges, the benefits of gene therapy are vast, and the field is rapidly advancing.⁶

In the context of cancer treatment, the application of genetic intervention typically involves the use of numerous agents. Small molecule agents such as cisplatin (CP), dox-

orubicin, and temozolomide suffer from drug resistance, making them unsuitable agents to suppress for some cancer types.^{7,8} Therefore, efforts have been directed toward using genetic interventions to target genes responsible for cancer growth and malignancy.^{9–11} Various genetic tools, including siRNA, shRNA, and the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, are utilized for targeting genes in cancer therapy. There are, however, limitations associated with the aforementioned tools, such as their off-targeting effects, degradation by enzymes and the presence of physiological impediments represented by the blood–brain barrier (BBB) and blood–tumor barrier.^{9,12–14} Hence, delivery systems should be developed to release genetic tools at the tumor site, enhancing their accumulation in cancerous cells and strengthening their effects against cancer cells.

The two primary categories for delivering genetic tools are viral and nonviral carriers. Special attention has been given to nonviral vectors due to their biocompatibility, safety, and lower immunogenicity compared with viral vectors.¹⁵ Besides, ligands can modify nonviral vectors to significantly enhance their selectivity toward cancer cells. Selecting a suitable vector is crucial for ensuring the efficacy of the treatment.¹⁶ Extensive research has been conducted on two types of gene carriers, namely nanoliposomes and polycationic vectors, for the purpose of conveying genetic material. Recently, nanoliposomes have emerged as a very promising contender owing to their distinct advantages over polycationic vectors. These lipid-based vesicles, which are very small in size, consist of amphiphilic lipid molecules. They have a wide range of uses and are commonly employed for administering drugs and gene therapy purposes. Nanoliposomes have




FIGURE 1 Advantages of nanoliposomes in gene therapy.

several advantages compared with polycationic vectors in the context of gene delivery. Their capacity to interact well with biological systems, lower likelihood of causing an immune response, ability to remain stable, flexibility in modifying their surface, and ability to be produced on a large scale make them appealing. Diverse nonviral vectors, such as dendrimers and nanospheres, have been utilized in gene therapy.¹⁷ Nevertheless, nanoliposomes, specifically, present a hopeful framework for cancer gene therapy, offering a combination of targeted delivery, adaptable cargo, and regulated release. These distinctive benefits have garnered significant interest in the field (Figure 1).

In conclusion, the present review emphasizes the potential of liposomes as nonviral vectors for cancer gene therapy. Through a comprehensive analysis, we aim to explore the role of liposomes in delivering genetic tools, discuss their methods of synthesis and biomedical application, review strategies for introducing them to the market, and highlight their promising prospects in advancing cancer gene therapy.

2 | LIPOSOME: BASICS, SYNTHESIS, AND BIOMEDICAL APPLICATIONS

Alec Bangham made the first identification of liposomes in 1965. Much effort has been made to implement their use for cancer therapy.¹⁸ There are two major categories of liposomes small and large unilamellar vesicles with particle size at the range of 100–250 nm.¹⁹ Among these, small unilamellar vesicles (SUVs) are those mainly applied for drug delivery.²⁰ Phospholipid molecules such as cholesterol and other helper lipids are utilized for liposome synthesis.²¹ Lipophilic fatty acid chains form the hydrophobic tail of phospholipid molecules, while hydrophilic phosphate ester groups form the polar head. A number of lipid molecules can be utilized for liposome synthesis that cationic, anionic, zwitterionic and poly (ethylene glycol) (PEG)ylated lipid are among them with the capacity of being esterified to generate various phosphoglycerides.²² In the formation of liposomes, cholesterol is preferred because it provides lipid membrane fluidity that is important for the stability of liposomal

carriers. Furthermore, in order to improve functionality, phosphate groups of small lipid molecules can be subjected to modifications.²³ Usually liposomes consist of one or more double-layered phospholipid vesicles (hydrophobic nature) surrounding an aqueous core.²⁴ They are ideal candidates for drug delivery due to increased absorption, enhanced half-life, reduced metabolism, and because they are minimally toxic to normal cells.²⁵ The liposome properties depend on size, charge, lipid composition, and synthesis method. Some liposome features that have improved their biomedical application include biocompatibility, stability, controlled release, and biodegradability.²⁶ Furthermore, surface modification of liposomes enables to selectively target certain cells, especially cancer cells.²⁷

2.1 | Synthesis

To date, various methods have been applied to synthesize liposomes. It is worth mentioning that for the various types of liposomes, such as SUVs, multilamellar vesicles (MLVs) and giant unilamellar vesicles (GUVs), different strategies have been applied for their synthesis. Electroformation, gel-assisted formation, and emulsion phase transfer are the methods used for GUV synthesis. The solvent injection is utilized for SUV synthesis, whereas microfluidics can be used to prepare SUVs and GUVs. Film rehydration and solid rehydration are applied to synthesize SUVs and MLVs. These methods determine liposome characteristics like size, yield, type, and polydispersity. For example, liposomes prepared using film rehydration, solid rehydration, and solvent injection display large polydispersity. At the same time, electroformation, gel-assisted hydration, emulsion phase transfer, and microfluidics generate liposomes with a low polydispersity.²⁸ One of the most important aspects of liposome preparation is that vesicle formation should occur at temperatures above the T_m of the utilized lipid. This is a major issue when synthesizing liposomes as it might affect the encapsulation of components and macromolecules sensitive to temperature. For example, proteins and DNA (deoxyribonucleic acid) are sensitive to high temperatures and may lose their function.²⁹ Various strategies can be applied when preparing liposomes; these can be subdivided into two major classes: solvent-free and solvent-displacement. In solvent-free methods, no organic compound is used for vesicle synthesis, and amphiphiles undergo hydration in an aqueous medium. In contrast, in the solvent displacement method, the organic solvent is utilized for dissolving amphiphiles and is then removed by placing them in an aqueous medium.^{30,31} Film rehydration, solid rehydration, electroformation, and gel-assisted hydration are solvent-free methods, while solvent

injection, emulsion phase transfer, and microfluidics are solvent displacement methods.²⁸

2.2 | Biomedical applications

Noteworthy, liposomes can be utilized for the treatment of various conditions. For example, in the context of diabetes mellitus, liposomes are applied for insulin peptide delivery.³² Liposomes can enter macrophages and significantly diminish the secretion of proinflammatory factors, leading to the amelioration of rheumatoid arthritis.³³ Liposomes can deliver anti-inflammatory mediators like interleukin-10 (IL-10) for treatment of atherosclerosis.³⁴ Liposomes are also effective in treating neurological disorders due to their ability to cross BBB; further, modification of their surface using transferrin (Tf) promotes their efficacy.³⁵ Liposomes are also widely applied in treating cancer,³⁶ to favor drug delivery to cancer cells. Besides, liposomes can increase the efficacy of chemotherapy agents in cancer therapy by providing targeted delivery at the tumor site.³⁷ The preclinical examinations have highlighted the role of liposomal nanocarriers in the cancer suppression.^{38,39} Of note, the biomedical application of liposomes is not limited to preclinical studies, as several liposomal drugs have been approved for clinical application. These include DaunoXome, for treating sarcoma; NX211 ovarian cancer therapy; Platar for solid tumors therapy, and so on.⁴⁰ Further attempts should be made to produce liposomal carriers containing genetic tools to be used in the treatment of cancer patients. Synthesis methods and various biomedical applications of nanoliposomes are given in Table 1.

3 | LIPOSOMES AND GENE DELIVERY

The application of nanoliposomes in cancer therapy has significantly progressed by incorporating various nucleic acid molecules, including short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), long noncoding RNA (lncRNA), and CRISPR/Cas9. Due to their unique properties, nanoliposomes serve as effective carriers for these nucleic acids, facilitating targeted and controlled delivery to cancer cells. siRNA and shRNA are utilized to silence specific genes associated with cancer, while miRNA regulates gene expression at the post-transcriptional level. lncRNA functions as a modulator of various cellular processes, providing additional layers of control. The revolutionary CRISPR/Cas9 system, used for precise gene editing, is also incorporated into nanoliposomes to target specific cancer-related mutations. This comprehensive approach, harnessing the potential of

TABLE 1 Synthesis methods of nanoliposomes and various biomedical applications.

Method	Liposomes	Biomedical applications	References
Freeze drying (lyophilization)	MLVs, LUVs, SMVs, SUVs	Vaccine delivery, drug delivery	41
Detergent removal (depletion)	MLVs, LUVs	In vitro biomembrane studies	42
Solvent (ethanol/ether) injection	SMVs, SUVs	Gene delivery	43
Reverse-phase evaporation	MLVs, LUVs	Cancer therapy, imaging agents	44
Bangham method	MLVs,	Drug delivery, diagnosis	45
Microfluidic (micro hydrodynamic focusing—MHF)	SUVs, LUVs	Imaging agents	46
Membrane contactor	MLVs,	Drug delivery	47

Abbreviations: LUVs, large unilamellar vesicles; SMVs, small multilamellar vesicles.

diverse nucleic acid modalities with nanoliposomal carriers, offers versatility. This section will discuss genetic tools used in cancer gene therapy.

3.1 | DNA and mRNA delivery

The effective and specific delivery of therapeutic genetic material is a critical component of the rapidly developing field of cancer gene therapy. Liposomes, which are tiny vesicles made of lipids, have emerged as a promising method for transporting DNA and mRNA. They provide a versatile platform for precise and controlled release within cancer cells. This section explores the role of liposomes in transporting DNA and mRNA in cancer gene therapy, highlighting their mechanisms, benefits, and current research trends. DNA and mRNA can be stabilized and protected from nuclease degradation by complexing them with positively charged lipids, which enables their delivery to target cells. The delivery process involves the adsorption of liposomes onto the cell surface, followed by endocytosis and release into the cell.⁴⁸ They offer several advantages, including encapsulation and protection of the DNA, improved cellular uptake, and targeted delivery. These benefits make liposomes an attractive option for researchers and clinicians seeking to develop effective and safe gene therapies for cancer treatment. Liposomes can be customized to improve surface properties and increase cellular uptake as drug delivery systems. This is particularly crucial in cancer gene therapy, where the efficient delivery of therapeutic DNA into cancer cells is essential for treatment efficacy. By modifying the surface properties of liposomes, researchers can optimize their ability to penetrate the cell membrane and deliver therapeutic agents directly to the target cells. The encapsulation method is a promising technique that can be used to protect DNA from enzymatic degradation and immune system recognition. Encapsulating DNA within liposomes allows the therapeutic DNA to be transported to target cells with greater stability.

This method ensures that the therapeutic DNA remains intact during its journey to the target cells, thereby increasing the efficacy of the treatment.⁴⁹ Significant advancements have been achieved in the fight against cancer using messenger RNA (mRNA) cancer vaccines. These vaccines employ mRNA to instruct cells to generate particular proteins associated with cancer, triggering a strong immune reaction against tumors. The mRNA-based vaccination stimulates an immune response against these specific targets by encoding antigens associated with tumor or cancer cells. The COVID-19 pandemic has expedited the advancement of mRNA technology through the swift manufacturing and approval of mRNA-based COVID-19 vaccinations. This momentum has positively impacted the progress of mRNA cancer vaccine research. Liposomal nanoparticles are a complex and diverse platform for delivering mRNA. They offer a protective, adjustable, and targeted method. As previously stated, the lipid content of liposomes may be adjusted to enhance stability, biocompatibility, and controlled release in mRNA transportation. Therefore, it protects the mRNA from enzyme degradation and guarantees its integrity while being transported to target cells.⁵⁰ A novel delivery system that employs the cationic peptide DP7 has been developed and modified with liposome immunoadjuvant properties. The primary objective of this system was to augment the expansion of dendritic delivery of mRNA encoding individualized neoantigens (DCs) and to enhance the activation of DCs. In preclinical studies, the subcutaneous administration of mRNA complexes encoding the neoantigen significantly stimulated the production of antigen-specific lymphocyte reactions.⁵¹ To summarize, liposomes constitute a diverse and promising platform for the transportation of DNA and mRNA in cancer gene therapy. Because of their capacity to encapsulate, shield, and transport genetic information to specific cells with improved specificity, they are regarded as crucial instruments for more efficient and individualized cancer therapies. The advantages of modifications of liposomes are given in Table 2. The combination of liposomal technology with cancer gene therapy has the

TABLE 2 Advantages of chemical modification of liposomes.

Chemical modification	Function	Advantages	References
PEGylation	PEGylation provides steric hindrance around nanoliposomes, protecting them from degradation in biological fluids. The presence of PEG chains on the surface of nanoliposomes prevents their recognition and uptake by immune cells, thus reducing their immunogenicity. It increases the hydrophilicity of nanoliposomes, leading to improved solubility and reduced aggregation in biological fluids.	PEGylation prolongs nanoliposome circulation time, enhancing therapeutic efficacy by reducing clearance by the reticuloendothelial system and allowing sustained delivery of RNA payloads to target tissues. Minimizes off-target effects and improves safety profile of nanoliposomal formulations. PEGylated nanoliposomes exhibit increased accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect.	52
Surface charge modification	Modifying the surface charge of nanoliposomes changes their electrostatic properties, which can impact how they interact with cells and tissues. Researchers can improve the binding affinity and uptake of nanoliposomes by adjusting their surface charge, resulting in better delivery of RNA payloads to target cells.	Nanoliposomes that have a positive charge can interact with cell membranes that are negatively charged in a more effective manner. This interaction results in an improved internalization and delivery of RNA payloads into the cells. Nanoliposomes can be designed with improved targeting specificity for specific cell types or disease sites by regulating the surface charge, thus reducing off-target effects. Modifying the surface charge of nanoliposomes can enhance their stability in biological surroundings by mitigating aggregation and opsonization.	53
Ligand conjugation	Conjugation of ligands enables the selective targeting of nanoliposomes toward cells or tissues that express corresponding receptors. Integration of targeting ligands onto the surface of nanoliposomes can augment their binding affinity and internalization by the target cells, thereby resulting in better transportation of RNA payloads.	Ligand conjugation allows nanoliposomes to selectively target cells expressing specific receptors. Delivery of RNA payloads is minimized with targeted nanoliposomes, reducing toxicity and side effects. Conjugating ligands is an approach that can be customized to aim various cell types or markers of diseases.	54
pH-sensitive lipids	pH-sensitive lipids respond to changes in pH by undergoing structural transitions, particularly in acidic environments like endosomes and lysosomes. They destabilize the liposomal membrane at low pH and promote fusion with the endosomal membrane, facilitating the release of RNA payloads into the cytoplasm for therapeutic effects.	Facilitate endosomal escape. pH-sensitive lipids change in acidic environments, like endosomes. This controls the release of RNA payloads within target cells, minimizing off-target effects.	55
Stealth lipids	Lipids that are known as stealth lipids are developed to reduce the identification by the immune system, particularly by the mononuclear phagocyte system (MPS) that includes macrophages and phagocytes. These lipids are usually made up of polyethylene glycol (PEG) chains, which create a hydrophilic polymer brush on the surface of nanoliposomes. The PEG chains produce a hydrated layer that prevents the absorption of opsonins and other serum proteins, thereby decreasing the identification and ingestion by phagocytic cells.	Nanoliposomes can evade detection by the immune system and remain in the bloodstream for a longer duration due to the presence of stealth lipids that confer stealth properties. Stealth lipids help reduce the activation of the immune system and the production of proinflammatory cytokines by minimizing recognition and uptake by phagocytic cells.	18

(Continues)

TABLE 2 (Continued)

Chemical modification	Function	Advantages	References
Aptamer conjugation	Aptamers have high affinity and specificity for their target molecules, making them useful for delivering nanoliposomes to diseased cells or tissues. This targeted approach minimizes off-target effects and improves the therapeutic efficacy of RNA payloads by enhancing the accumulation of nanoliposomes at the desired site.	By conjugating aptamers, nanoliposomes can be delivered selectively, reducing the exposure of RNA payloads to the entire body. This approach helps to minimize the potential side effects and toxicity of the treatment. Utilizing aptamer conjugation is a flexible approach that can be customized to focus on a diverse set of disease markers or cell types.	56

potential to greatly impact cancer treatment by providing new opportunities for therapeutic intervention at the genetic level.

3.2 | SiRNA delivery

RNA interference (RNAi) based on siRNA enables gene silencing at the posttranscriptional level. It provides an effective degradation or translation inhibition of the target mRNA.⁵⁷ RNAi is preferable to conventional therapeutics, including well-known gene silencing mechanisms, due to the fast and highly selective binding and the ability to target any genes, including those encoding for undruggable protein products.⁵⁸ Typical siRNAs have a length of 21–23 nucleotides and can be derived from long pieces of double-stranded RNA using specific enzymes.⁵⁹ The RNAi therapy using siRNA represents a novel form of treatment for different diseases, including cancer, viral infections, ocular diseases, and another disease in which gene dysregulation occurs.^{60,61} However, some challenges are associated with siRNAs gene knockdown, including degradation by nucleolytic enzymes, immune cell uptake, and insufficient tissue penetration.⁶² Therefore, nanoscale delivery systems have been developed to optimize siRNA delivery to increase its application in the cancer therapy.^{10,63} Liposomes can internalize siRNA into tumor cells via endocytosis (clathrin-mediated endocytosis and micropinocytosis), and through cell membrane cholesterol-dependent processes.⁶⁴ In the next sections, we discuss how liposomes can be ideal candidates for siRNA delivery and suppressing cancer progression.

3.2.1 | SiRNA- and antitumor compound-loaded liposomes

To date, a wide variety of antitumor compounds have been developed for cancer therapy. In this regard, nanocarriers for combined delivery of anticancer compounds and

genetic tools might be considered. This section discusses using liposomes in the codelivery of siRNA and anticancer compounds in the cancer setting. The resistance of cancer cells to apoptotic cell death is mainly mediated by signal transducer and activator of transcription 3 (STAT3).^{65–67} Besides, this pathway promotes metastasis through the induction of epithelial-to-mesenchymal transition (EMT) and participating in the drug resistance.^{68–71} Liposomes containing curcumin and STAT3–siRNA have been developed to treat skin cancer. These cationic liposomes represent a noninvasive topical iontophoretic method. These liposomes enter the cancer cells through clathrin-mediated endocytosis. Upon uptake, these nanocarriers induce apoptosis and significantly diminish the cancer cell growth.⁷² In another study, the role of curcumin- and STAT3–siRNA-loaded liposomes was evaluated in the context of skin cancer therapy. Interestingly, compared with intratumoral administration, iontophoretic administration is beneficial in reducing tumor progression, suppressing growth in vivo and inducing apoptosis; this suggests the potential for siRNA- and curcumin-loaded liposomes in the cancer treatment.⁷³

Paclitaxel (PTX) is a well-known chemotherapeutic agent that can suppress the proliferation of cancer cells by inducing cell cycle arrest.^{74,75} This results in alterations of microtubules and by preventing microtubule depolarization.⁷⁶ PTX resistance is a common phenomenon, and one potential strategy to overcome it could rely on using siRNA.⁷⁷ PTX- and survivin–siRNA-loaded cationic liposomes have been developed to target cancer stem cells for treating brain glioma. After successful penetration through the BBB, liposomes selectively targeted glioma cells and brain microvascular endothelial cells (BCECs). Noteworthy, these liposomes induced apoptosis only in glioma stem cells but not in BCECs, showing their high biocompatibility. In glioma tumor-bearing mice, administration of siRNA- and PTX-loaded liposomes ameliorates survival. This experiment shows that siRNA-induced downregulation of the survivin gene, a prosurvival mechanism, sensitizes cancer cells to PTX-mediated cell death.⁷⁸

The tumor microenvironment (TME) is a complex space containing different types of cells, such as fibroblasts, cancer stem cells, and endothelial and immune cells.⁷⁹ The competition among cancer cells for proliferation results in hypoxia. Increasing evidence has demonstrated the role of hypoxia in inducing chemoresistance.^{5,80–81} Targeting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) might be important in cancer therapy due to a decrease in ATP levels and inhibition of autophagy. For this purpose, GAPDH-siRNA- and PTX-loaded liposomes have been designed. The liposome preparation was performed using a new strategy known as cryogenic inner-outer dual reverse phase emulsion. The preclinical experiments have approved the potential of liposomes for downregulating GAPDH and enhancing the efficacy of PTX in cancer chemotherapy. Importantly, this strategy overcomes the hypoxia-mediated drug resistance in cancer cells like HeLa and MCF-7.⁸² A similar strategy was adopted to deliver docetaxel (DTX) for the cancer therapy. Since angiogenesis induction favors cancer progression through the vascular endothelial growth factor (VEGF),^{83–85} work has been done to develop VEGF-siRNA- and DTX-loaded liposomes. Due to surface modification of liposomes with Angiopep-2 and tLyP-1, liposomes could penetrate the cancer cells through receptor-mediated endocytosis, leading to enhanced intracellular accumulation of siRNA and DTX. Furthermore, the liposome structure provides siRNA and DTX escape from endosomes and lysosomes. Additional investigations revealed that VEGF-siRNA- and DTX-loaded liposomes effectively induce apoptosis and suppress angiogenesis in glioblastoma therapy. Notably, no immune reaction is observed, confirming the high biocompatibility of these liposomal nanocarriers. The combination of two receptor-specific peptides, Angiopep-2 and tLyP-1, mediated the liposome, as shown in Figure 2. Gene silencing of VEGF, antiangiogenesis, and apoptosis of tumor cells cooccurred in this process.⁸⁶

3.2.2 | Surface-modified liposomes

Surface modification of liposomes with different ligands and polymers is considered a vital strategy in cancer therapy since this method can significantly promote the selectivity of liposomes toward cancer cells. Therefore, it is paramount to identify which receptors on cancer cells can be targeted and which agents can be utilized for the surface modification of liposomes. This section will describe surface-modified liposomes for siRNA delivery in cancer treatment.

Cancer progression involves different cells within the body, including TME. Th17 cells, a type of cell, produce a substance called IL-17, which facilitates the metastasis of

gastric cancer cells. Recent studies have revealed that the Tetraspanin 1 (TSPAN1) protein plays a role in activating CD4+ cells into Th17 cells. A treatment for stomach cancer has been devised that consists of a liposome polycation-DNA complex loaded with TSPAN1-siRNA and modified with Th17 antibodies. By impeding the conversion of CD4+ cells to Th17 cells, this approach actively impedes the progression of stomach cancers.⁸⁷ The preparation of liposomes for siRNA delivery has shown potential with the use of DC-Chol cationic lipids and DOPE neutral lipids. However, the use of cationic liposomes has several limitations, including their interaction with negatively charged plasma cells such as blood cells and serum proteins.⁸⁸ This interaction leads to their rapid clearance and elimination from the circulation, which hinders their therapeutic application. Moreover, cationic liposomes tend to aggregate, which further complicates their use in siRNA delivery.⁸⁹

To overcome these challenges, PEGylation has been used to enhance the stability of liposomes in serum, prevent aggregation, and improve their circulation in the bloodstream. The PEGylated cationic liposomes have been shown to enhance the efficacy of siRNA in downregulating the expression of kinesin spindle protein to suppress tumor growth in ovarian tumor therapy. The PEGylation also reduces the absorption and metabolism by the liver, while increasing accumulation at the tumor site. This has been attributed to the reduced blood clearance and promoted escape from immune recognition.⁹⁰ It is preferable to form a complex between siRNA and polyethyleneimine (PEI), which has a positive charge. This complex formation favors the stability and ability of the liposomes to interact. The PEGylated liposomes have been used in cervical tumor therapy, where they have been shown to increase siRNA accumulation in cancer cells and reduce levels of human papillomavirus (HPV) gene. Modification with AG86 targeting peptide-amphiphile binding to $\alpha 6 \beta 4$ integrin has also been included to enhance selectivity toward cancer cells.⁹¹ These studies suggest that liposome PEGylation is a promising strategy for siRNA delivery in cancer treatment. The PEGylation approach has been shown to enhance the stability of liposomes, reduce blood clearance, and improve their accumulation at the tumor site. Furthermore, the use of AG86 targeting peptide-amphiphile binding to $\alpha 6 \beta 4$ integrin enhances their selectivity toward cancer cells. Therefore, the application of PEGylated liposomes in siRNA delivery could be a potent therapeutic strategy for cancer treatment.

Although some studies have reported that using PEGylation on liposomes has positive effects, there are also concerns. These concerns are serious enough to consider alternatives to PEG. When PEGylated nanoparticles are used, they might stop nanoparticles from interacting with cells, reduce cellular internalization, trigger IgM antibody




FIGURE 2 The application of liposomal nanostructures in siRNA and DTX delivery for cancer suppression. The conjugation of liposomes with Angiopep-2 and tLyP-1 favors their selectivity toward cancer cells. Liposomes penetrate into the cells through endocytosis and provide an endosomal escape. The increased intracellular delivery of DTX and siRNA-VEGF suppresses cancer growth and angiogenesis, therefore representing a promising tool for contrasting cancer cells. siRNA, small interfering RNA; DTX, docetaxel; EPR, enhanced permeability and retention; mRNA, messenger RNA; SPC, soybean phosphatidylcholine; DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; VEGF, vascular endothelial growth factor. Reproduced with permission from Ref. 86, Copyright (2014), Elsevier.

production, cause accelerated blood clearance, and activate complement systems.^{92–96} Hence, as an alternative to PEG, PEI has been suggested. PEI has a high positive charge that allows siRNA to condense through an electrostatic interaction.^{97,98} Furthermore, PEI can break down endosomal vesicles through the “proton-sponge effect.”⁹⁹ PEI-modified liposomes were employed to deliver siRNA and PTX for the treatment of drug-resistant tumors, and they exhibited superior penetration capabilities compared with PEGylated liposomes in 3D spheroids.

3.2.3 | Advanced liposomes

pH-responsive liposomes

Compared with normal and healthy tissues, cancer tissues display a more acidic pH (6.5–7).¹⁰⁰ Nanoparticles

are extensively applied in increasing cancer site accumulation via enhanced permeability and retention (EPR) impact.^{101–106} The low pH at the tumor site derives from the rapid progression of tumors and poor blood supply.¹⁰⁷ To provide specific tumor site delivery, pH-responsive nanocarriers have been developed. pH-sensitive nanocarriers are synthesized using various types of polymers. Cationic polymers with amino groups, anionic polymers with carboxyl groups, polymers with imidazole groups, poly (β -amino esters), hydrazone, acetal, ortho ester, or vinyl ether-bonded polymers, and intracellular responsive cationic polymers are some of the commonly used polymers for this purpose. Polymers with imidazole groups, polymers with hydrazine linkages, and polymers with acetal or ester linkages are among those most frequently utilized for the synthesis of pH-sensitive nanocarriers. Noteworthy, pH-sensitive liposomes have been designed

in favor of cancer gene therapy via siRNA delivery. The selected polymer should be cleavable at the pH of the tumor site. Sometimes, these polymers favor the internalization of liposomes in the tumor cells. There are numerous advantages derived from the inclusion of these polymers into liposomes to make them pH-responsive. Recently, siRNA delivery has been made by dioleoylphosphate–diethylenetriamine conjugate (DOP–DETA)-modified liposomes. This polymer conjugate was pH sensitive due to presence of triamine and can release siRNAs at the tumor site, enhancing their accumulation in cancer tissues. Noteworthy, it appears that this modification enhances the ability of liposomes to fuse with the membrane and mediates their penetration into cancer cells through the macropinocytosis.¹⁰⁸ Based on this evidence, pH-sensitive liposomes have several advantages, and the choice of polymer to associate is important in this regard. It has been reported that pH-sensitive liposomes can provide synergistic effects in cancer therapy via the codelivery of antitumor compounds and siRNA.

Modifying liposomes with carboxymethyl chitosan has also resulted in the formation of pH-sensitive nanocarriers. Loading sorafenib, an antitumor agent, and VEGF–siRNA results in a synergistic effect that induces apoptosis in hepatocellular carcinoma cells.¹⁰⁹ In vivo experiments on tumor-bearing mice show that pH-sensitive liposomes can reach the tumor site more rapidly than other organs, exhibiting specificity toward cancer cells and tissues.¹¹⁰ The basis for developing pH-sensitive liposomes depends on structure collapse in mildly acidic pH, releasing the cargo into the tumor cells.¹¹¹ Combining different polymers can accelerate polymer decomposition at low pH, thus favoring siRNA release and improving the chances of success of cancer therapy. PEGylation of liposomes leads to siRNA protection against degradation and intracellular delivery of siRNA within endosomes. Embedding 1,2-dioleoyl-3-dimethylammonium-propane, a titratable lipid, into these cationic liposomes results in enhanced cationic nature of liposomes. Hence, at mildly acidic pH of TME, polymer degradation along with membrane fusion occur, this being important for the siRNA delivery.¹¹² Overall, these studies indicate that liposomes can be modified with different polymers to render them pH-sensitive; this feature enhances transfection efficiency and results in increased siRNA delivery to tumor cells and ameliorated gene knockdown efficacy.

Redox-responsive liposomes

Tumor cells have a redox potential determined by oxidation and reduction levels of glutathione (GSH) and NADPH. In reducing conditions, GSH levels increase, modulating the redox microenvironment of cancer cells.^{113,114} GSH controls redox levels by reducing reactive

oxygen species (ROS) levels and through the formation and fragmentation of disulfide bonds.^{115–117} Various redox-responsive nanocarriers have been developed for cancer therapy to prolong their time in circulation and provide degradation after internalization, thus facilitating the drug and gene delivery.¹¹⁸ Along with this, redox-responsive liposomes have been developed for siRNA delivery. Although a few studies have evaluated redox-responsive liposomes' role in siRNA delivery, substantial work is still required to assess the potential of these liposomes in cancer therapy. Previous work was done to deploy redox-responsive oligopeptide liposomes in mammary tumor therapy via survivin–siRNA and PTX. To develop redox-responsive liposomes, cationic lipids (LHSSG2C₁₄), natural soybean phosphatidylcholine (SPC), and cholesterol have been combined. Then, PTX was loaded in the liposome bilayer via hydrophobic interactions, while siRNA was attached to cationic liposomes through electrostatic interactions. The use of cationic lipid (LHSSG2C₁₄) in these liposomal nanocarriers is advantageous because it enables the endosomal escape of nanoparticles due to the proton sponge of histidine in its structure; further, in the reducing environment of the cytoplasm, the disulfide bond in its structure is cleaved, leading to the cargo release in a redox-responsive manner. The preclinical studies demonstrated that these redox-responsive liposomes effectively suppress cancer growth and pulmonary metastasis due to high transfection efficiency.¹¹⁹ However, more studies are needed to modify liposomes using various polymers to make them redox-responsive and increase siRNA delivery in cancer therapy.

Light-responsive liposomes

External stimuli like light are beneficial in cargo delivery to tumor sites for therapeutic purposes.¹²⁰ Light is a clean and spatial stimulus that can be applied for diagnosis, cargo release, and disease therapy by modulating parameters such as wavelength, polarity, duration and irradiation intensity.¹²¹ Furthermore, light can induce cargo release in phototherapy, improving capacity in the disease therapy.¹²² Ultraviolet (UV) is the most common type of irradiation applied for light-responsive nanocarriers, given the high number of polymers responsive to UV and providing enough energy for cleavage and cargo release.¹²³ Such a strategy has been developed to deliver siRNA at the tumor site using light as an external stimulus.¹²⁴ Like other kinds of smart liposomes for siRNA delivery, the polymer type is important for developing light-responsive liposomes in cancer therapy. In a previous work, liposomes bearing photolabile-caged peptide (PCP) were used for siRNA delivery. In this case, lysine residues on the cell-penetrating peptide (CPP) were coated by protective groups to form PCP. After exposure to near-infrared (NIR)

irradiation, the protective groups are cleaved so that CPP re-gains functionality. Then, CPP enhances the internalization of liposomes into cancer cells, increasing siRNA delivery at the tumor site.¹²⁵ The application of NIR is due to damage in cells caused by UV. Figure 3A illustrates the operating mechanism of these liposomes that have been dual-modified. Exposure to every type of liposome-loaded c-myc siRNA resulted in an abundance of apoptotic cells, as shown in Figures 3B and C. Cells treated with NIR-pretreated pcCPP/NGR-LP and loaded with c-myc siRNA showed the highest percentage of induced apoptosis (Figure 3D). In this case, lysine residues of CPP are caged with photosensitive groups to neutralize charges. Exposure to NIR is associated with uncaging of photosensitive groups, favoring interactions of CPP with the cell membrane, and mediating internalization of siRNA into tumor cells.¹²⁶ These advanced liposomal nanoformulations are highly relevant for tumor therapy by elevating siRNA internalization. The use of surface-modified liposomes as delivery vehicles for siRNA and antitumor agents, which enhance cancer suppression and facilitate their internalization into cancer cells via endocytosis, is depicted in Figure 3E.^{127–136} Table 3 summarizes liposomes applied for siRNA delivery in cancer treatment.

3.3 | shRNA delivery

shRNAs are additional genetic tools applied for cancer treatment. ShRNAs belong to the family of short noncoding RNAs (ncRNAs) and downregulate gene expression similarly to siRNA. Both shRNAs and siRNAs are short ncRNAs that can be utilized for gene knockdown. In the previous section, we discussed the siRNA role and liposome delivery. Like siRNA, the use of shRNA has some caveats. For this reason, a variety of vectors have been designed for shRNA delivery; these produce short duplex RNAs in cells to then reduce gene expression.¹⁴⁸ The process of gene regulation by shRNA consists of several steps. After vectors deliver shRNA to cells and following the generation of hairpin RNAs in the nucleus, cytoplasmic translocation occurs to provide shRNA cleavage by Dicer and its subsequent transformation into siRNA. Then, the target gene's expression decreases upon siRNA's embedding into RISC.¹⁴⁹ From this point onward, there is a high similarity between siRNA and shRNA in gene silencing. This section aims to show how liposomes can be applied to deliver shRNA in cancer therapy.

3.3.1 | Enhancing shRNA efficiency

The main advantage of using liposomes in shRNA delivery is that these nanocarriers can provide long-term silenc-

ing of target genes. Viral particles can mediate long-term silencing via the siRNA delivery.¹⁵⁰ Liposomal vectors, however, are preferable because of their safety profile. In this regard, viral vectors have been associated with inflammation, immunogenicity, mutagenesis and, more importantly, risk of oncogenic transformation.^{151,152} Furthermore, shRNA effects can last for a long period.¹⁵³ That is why studies have now focused on developing liposomes for shRNA delivery and cancer suppression. Recently, PEGylated cationic liposomes have been developed using the thin-film hydration method. The plasmids expressing Eg5 shRNA were generated by inverted terminal repeat (ITR) sequences. This process produced Eg5 hairpin RNA, which was placed under the control of the U6 promoter. Utilizing ITRs in configuring plasmids containing Eg5 shRNA allowed the efficient expression of the desired genetic material.¹⁵⁴

The next step would be the identification of molecular pathways involved in cancer survival and proliferation, followed by the administration of associated shRNA to downregulate some of these pathways. The upregulation of survivin is a common finding in different cancers and is associated with apoptosis inhibition.^{155–157} Survivin–shRNA-loaded liposomes have been applied for the treatment of various cancers including breast, liver, melanoma, and cervical cancers. Downregulation of survivin by liposomes occurs at mRNA and protein levels, this being relevant for sensitizing cancer cells to apoptosis.¹⁵⁸ Another important target in cancer therapy is thymidylate synthase (TS), an enzyme involved in tumoral DNA biosynthesis and overexpression in the ovarian cancer.^{159,160} To limit peritoneal dissemination of ovarian cancer, TS-shRNA-loaded cationic liposomes have been applied. These loaded liposomes, containing different concentrations of TS-shRNA (0.5, 1, and 2 mg) were injected into mice via intraperitoneal administration. Further investigations showed that combining shRNA-loaded liposomes with PTX, an antitumor agent, enhanced the drug's antitumor effects. The interesting note is that shRNA-loaded liposomes, administered intraperitoneally, were detected in the ascites 24 h later, therefore showing high stability in the peritoneal cavity. Furthermore, their systemic toxicity was minimized being absent in the bloodstream.¹⁶¹ The administration route is also an important aspect that impacts the liposome safety profile, as demonstrated in the case of intraperitoneal injection.

Another way to improve the siRNA delivery capacity of liposomes is to combine them with focused ultrasound (FUS). The presence of BBB diminishes efficacy in brain cancer therapy. In addition to its diagnostic applications, FUS can be utilized for opening BBB in a noninvasive and reversible manner.¹⁶² This is important for enhancing the efficiency of liposomes in shRNA delivery and




FIGURE 3 A visual representation of pcCPP/NGR-LP and the measurement of c-myc mRNA through qRT-PCR. (A) Preparation of dually modified liposomes for targeted delivery at the tumor site following modification with NGR ligand. Exposure of these liposomes to NIR light results in the release of PG and subsequent interaction of CPP with the cell membrane to mediate penetration of liposomes into cancer cells; (B) application of Western blot analysis for investigating expression level of c-myc protein. (C) The presence of apoptosis. (D) Cell apoptosis following exposure to different formulations. Reproduced with permission from Ref. 126. Copyright (2015), Elsevier. (E) Surface-modified liposomes for the delivery of siRNA along with antitumor agents to achieve cancer suppression. This surface modification promotes penetration of liposomes into cancer cells through endocytosis. Figure was created with BioRender.com.

T A B L E 3 The advantages of liposomal nanostructures in siRNA delivery.

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modification gene and/or drug	In vitro/In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
siRNA- and phase fusion protein-targeted liposome	–	–37.93 mV	90.5%	DMPG/TVLP PRDM14	In vitro	MCF-7 cells	Breast cancer	Fusion phase proteins provide specific targeting of breast cancer cells Downregulation of target gene in cancer cells Targeted siRNA-protein-liposomes were found to downregulate the PRDM14 gene by 44%.	¹³⁷
ICAM-1-targeted liposomes	123 nm	–8 mV	46.7%	ICAM-1 Lcn2	In vitro	MDA-MB-231 cells	Triple negative breast cancer	Lcn2 downregulation leads to VEGF inhibition Suppressing angiogenesis Suppressing tumor growth VEGF was significantly reduced by 58 ± 1% in the CM of MDA-MB-231 cells treated with ICAM-Lcn2-LP.	¹³⁸
Thermal and magnetic dual-responsive liposomes	90 nm	19.88 mV	87.12%	FAM	In vitro In vivo	MCF-7 cells MCF-7 tumor-bearing female	Breast cancer	High cellular uptake Endosomal escape Effective gene silencing High antitumor activity in vitro and in vivo Treatment with siRNA-CPPs/TML (activated) provided the best antitumor efficacy (228.83 ± 20.16 mm ³).	¹³⁹
F3-targeted liposomes	–			PLK1	In vitro	PC3 cells	Prostate cancer	Reducing cell viability Downregulation of PLK1 gene at mRNA and protein levels Enhancing antitumor activity of paclitaxel against cancer cells Inducing G2/mitosis arrest PC3 and HMEC-1 cell viability decreased by 57.0 ± 9.03% and 39.4 ± 9.86%, respectively.	¹⁴⁰

(Continues)

TABLE 3 (Continued)

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modification gene and/or drug	In vitro/In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
PSA-responsive PSMA-mediated multifunctional liposomes	208.4 nm	2.79 mV		DSPE-PEG ₂₀₀₀ -ACPP, DSPE-PEG ₂₀₀₀ -CPP, PLK1	In vitro In vivo	PC3 cells Animal model	Prostate cancer	Reducing nonspecific uptake Improving prostate cancer cell recognition Downregulating PLK1 and potentiating apoptosis induction in cancer cells Providing endosomal escape Entering into cancer cells through macropinocytosis and clathrin-mediated endocytosis Pronounced inhibition was noted in the siPLK-1-contained AF-L group at both the level of mRNA (~30% of the 5% glucose control) and protein.	¹⁴¹
Transferrin-conjugated PEG liposomes	117.2 nm	-11 mV	92%	BCR-ABL	In vitro	K562 cells	Leukemia	Reducing gene expression and decreasing viability of cancer cells There was an approximately 60% decrease in the expression of the BCR-ABL gene compared with the control sample.	¹⁴²
Cationic liposomes	100–150 nm	3–6 mV	90%	CDC20 paclitaxel	In vitro In vivo	IMR-32 and HEK-293 cells Neuroblastoma model	Neuroblastoma	Silencing gene Inducing cell death (80%) Apoptosis induction Delaying tumor growth in vivo Synergistic impact with paclitaxel	¹⁴³
Carboxymethyl chitosan-modified cationic liposomes	200 nm	-10.6 mV	90%	Sorafenib	In vitro In vivo	HepG2 cells Kunming mice bearing H22 tumor model	Hepatocellular carcinoma	The pH-sensitive nanocarriers releasing drug and gene at pH 6.5 Sufficient delivery of siRNA to tumor site The tumors of the CMCS-Sf-CL group were significantly smaller in tumor volume (300 mm ³) compared with the control groups.	¹⁴⁴

(Continues)

TABLE 3 (Continued)

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modification gene and/or drug	In vitro In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
cRGD grafted liposomes	118.36 nm	11.23 mV	82.93%	RRM1	In vitro In vivo	A549 cells Animal model	Lung cancer	High targeting capacity due to surface modification with cRGD Protection of siRNA against serum nucleases High stability in the presence of serum Partial hemolysis potential Reducing gene expression Suppressing cancer progression in vitro and in vivo cRGD-CPE liposomes (2%) showed 24.2 ± 3.4% gene expression.	145
CPT-PCB cationic liposomes-Prodrug liposomes	100–200 nm	25 mV	65%	PLK1 camptothecin	In vitro	HeLa cells	Cervical cancer	Acting in a pH-sensitive manner Rapid release of siRNA after 4 h incubation due to protonation of PCB High accumulation in nucleus Prolonged release Apoptosis induction Synergistic impact Simultaneous administration of siPlk1 with the CPT-PCB6 system increased cell apoptosis by 63.6% with a synergistic effect.	146
Folate receptor-targeted liposomes (FA-DOX/siRNA-L)	150 nm	43.9 mV	Up to 89.3%	Bmi1 doxorubicin	In vitro In vivo	HeLa, KB, Hep3B, A549, Huh7, MCF-7, and LO2 cells	Different cancers	Suppressing tumor growth in vitro and in vivo Reducing Bmi1 gene expression High accumulation due to modification with folate Synergistic impact between doxorubicin and siRNA Tumors treated with FA-DOX/siRNA-L have the smallest sizes (248 mm ³).	147

therefore in the treatment of brain tumors.¹⁶³ Furthermore, ultrasound-targeted microbubble destruction significantly enhances the potential of shRNA-loaded liposomes in cancer suppression.¹⁶⁴ Overall, all these studies support the use of liposomes as carriers for shRNA delivery and cancer treatment. Various genes like Hsp70, eIF3i, and WT1 have been targeted by shRNA-loaded liposomes and more studies are required to target additional molecular pathways responsible for cancer progression.^{18,165,166}

3.3.2 | Enhancing chemotherapy efficacy

The application of genetic tools such as shRNA affects the proliferation and invasion of cancer cells and regulates their response to therapy. Inducing cell death such as apoptosis is a common and important strategy. Antitumor compounds, both synthetic and natural ones, can induce apoptosis.^{167–169} This strategy is known as chemotherapy and is considered the gold standard in cancer treatment. However, since cancer cells can activate DNA damage repair mechanisms or trigger tumor-promoting pathways to prevent apoptosis, chemoresistance can develop.¹⁷⁰ Among the different strategies applied to reverse chemoresistance, the use of shRNA has been considered, since this genetic tool can downregulate expression of genes like WT1, AMBRA1, Bcl-xL, and PLK1 to eventually enhance the chemosensitivity of cancer cells.^{171,172} The advantage of using liposomes is that they can promote gene silencing efficiency of shRNA, and simultaneously, provide a platform to mediate shRNA and anticancer compound codelivery and achieve a synergistic effect in cancer therapy. To date, a variety of experiments have applied shRNA-loaded liposomes in cancer chemotherapy. Cationic liposomes are important tools in gene delivery due to their low immunogenicity and ease of synthesis.¹⁷³ Their transfection efficiency, however, is low restricting their application for cancer treatment.¹⁷⁴ Therefore, surface modification of liposomes with agents such as folic acid (FA) could enhance their selectivity toward cancer cells.¹⁷⁵ The shRNA possesses a negative charge, and cationic liposomes can be successfully applied for their delivery. Gemini surfactants are applied to synthesize cationic liposomes because of their positive charge, presence of multivalent polar headgroups and capacity in condensing negatively charged DNA.^{176,177} To enhance the efficacy of therapy against hepatocellular carcinoma, thioredoxin 1-shRNA- and doxorubicin-loaded cationic liposomes have been developed. Cationic liposomes containing gemini surfactants with symmetrical C16 aliphatic chains (L16-2-16) possess high cellular uptake and ability in DNA condensation. Their modification with FA promotes their penetration into cancer cells via targeting folate receptors

and inducing lipid raft/caveolae-dependent endocytosis. The shRNA/doxorubicin complex has been combined with cationic liposomes through electrostatic interactions. The complex was successful at reducing cell viability, inducing apoptosis.¹⁷⁸ Besides, magnetic cationic liposomes with the capacity to codeliver STAB1-siRNA and doxorubicin have been deployed to effectively treat gastric cancer. The preclinical experiments confirmed the role of shRNA- and doxorubicin-loaded liposomes in decreasing cancer growth. This codelivery approach is more effective than single delivery, promoting the synergistic impact of doxorubicin and STAB1-shRNA.¹⁷⁹ In addition to doxorubicin, liposomes are able to mediate targeted delivery of DTX as another potent anticancer compound.^{180,181} Furthermore, shRNAs and associated delivery systems have been also applied in combination with DTX.^{182,183} In fact, the aim of using liposomes as nanostructures is to mediate targeted delivery that is of interest in enhancing the potential of shRNA in gene silencing. Such a strategy not only disrupts tumor-promoting molecular pathways but also triggers the sensitivity of tumors to the chemotherapy.¹⁸⁴ Collectively, this evidence supports the use of shRNA-loaded liposomes to favor the cancer chemosensitivity.¹⁸⁵

3.3.3 | Advanced liposomal nanocarriers

In Section 3.1, we discussed different types of smart liposomes for siRNA delivery. Comparably, advanced liposomal carriers have been designed for the delivery of shRNA. To date, only pH- and GSH-sensitive liposomes have been applied for shRNA delivery in cancer treatment and, in this regard, more experiments are needed. Recently, pH- and GSH-sensitive liposomes containing shRNA targeting survivin have been developed for the therapy of breast cancer. Liposomes were prepared using a layer-by-layer method, and polysaccharides (i.e., chitosan and hyaluronic acid) were utilized for surface modification to provide redox sensitivity and favor entrance into cancer cells by endocytosis. Survivin-shRNA was then loaded into liposomes. The resulting product was HA/HAase/CS/liposome/survivin-shRNA (HCLR), as shown in Figures 4A and B. Thanks to the negative charge provided by hyaluronic acid, these liposomes demonstrated high stability in the bloodstream. Exposure to mildly acidic pH of TME (pH = 6.5–6.8), results in hyaluronic acid de-shielding and in protonation of chitosan, confirmed with alteration of zeta potential from −23.1 to +29.9 mV. Further, the exposure of liposomal nanocarriers to 10 mM GSH induces shRNA release. By increasing cellular uptake, shRNA-loaded liposomes successfully were able to reduce survivin expression and suppress cancer growth.¹⁸⁶ These liposomes have been




FIGURE 4 HCLR Nanocarrier fabrication and in vivo gene delivery targeting. (A) Preparation of liposomal nanocarriers that are pH- and redox-sensitive for shRNA release at the tumor site. (B) Synthesis pathway. Reproduced with permission from Ref. 186, Copyright (2020), American chemical Society. (C) Similar to siRNA, the efficacy of shRNA in gene regulation can be improved using liposomes for their delivery. Surface modifications of liposomes not only improve their biocompatibility but also enhance their selectivity toward cancer cells. Upon silencing of the target gene, proliferation and metastasis of cancer cells are affected. Figure was created with BioRender.com.

utilized for the codelivery of shRNA and chemotherapeutic compounds. Targeted delivery of DTX and sirtuin-1 (SIRT1)-shRNA by liposomes leads to a significant decrease in tumor burden. Furthermore, pH-sensitive liposomes are more effective in breast cancer therapy compared with non-pH-sensitive liposomes and clinical counterparts like Taxotere. shRNA-loaded liposomes that affect the proliferation and metastasis of cancer cells by silencing the target gene in cancer treatment are summarized in Figure 4C and Table 4.¹⁸⁷

3.4 | MicroRNA delivery

miRNAs are key members of ncRNAs. Most experiments related to ncRNAs include miRNAs, supporting their role in different diseases. miRNAs are endogenous, short ncRNAs 18–24 nucleotides long and capable of downregulating gene expression upon binding to the 3'-untranslated region (3'-UTR) of mRNA. miRNAs exert their regulation at the posttranscriptional level.^{189–192} The miRNA biogenesis process starts from the nucleus. It is followed by translocation to the cytoplasm, where different enzymes such as Drosha, Dicer, and RNA polymerase II play a significant role. miRNA gains its full function when embedded into an RNA-induced silencing complex (RISC) and interacting with Argonaute.¹⁹³ MiRNAs regulate biological events such as apoptosis, proliferation, metastasis, and therapy response. They are dysregulated in different diseases, including cancer, and regulating their levels is important in the cancer therapy.^{76,194,195}

3.4.1 | Codelivery

As mentioned in the previous sections, chemoresistance represents an increasing challenge in treating cancer patients, and novel strategies should be applied to overcome this problem. Gene therapy using miRNAs could be considered a promising strategy in this regard. Doxorubicin has been extensively applied in the treatment of hepatocellular carcinoma, and its coadministration with icaritin enhances cancer elimination by induction of immunogenic cell death.¹⁹⁶ Enhancing the expression of miRNAs is another strategy for potentiating the antitumor activity of doxorubicin.¹⁹⁷ Downregulation of miRNA-375 occurs in doxorubicin-resistant cancer cells, and enhancing miRNA-375 expression might help reverse drug resistance.¹⁹⁸ To effectively treat hepatocellular carcinoma, miRNA-375- and doxorubicin-loaded liposomes have been developed. First, miRNA-375 release by liposomes significantly diminishes the progression of hepatocellular carcinoma by apoptosis induction. In this case, upregu-

lation of Bax, caspase-3, JNK, and p38 occurs, as shown in Figure 5A. Furthermore, miRNA-375 can stimulate cell cycle arrest (G2/M phase) and impairs cancer progression by downregulating molecular pathways such as AEG-1, YAP1, and ATG7. Importantly, miRNA-375-loaded liposomes can reduce the level of multidrug resistance gene 1 (MDR1) to enhance therefore the doxorubicin sensitivity of hepatocellular carcinoma cells. Compared with the control group in gross morphology, the other groups showed apparent suppressive effects of tumor growth (Figure 5B). Examination of Figures 5C and D shows that the groups treated with L-miR-375/DOX-NPs maintained permanent tumor suppression, had the smallest volume, and no significant decrease in body weight was seen among these groups.¹⁹⁹

MiRNA-101 is another tumor-suppressor factor that diminishes myeloid cell leukemia 1 (Mcl-1) expression and promotes chemosensitivity (doxorubicin).²⁰⁰ Codelivery of miRNA-101 and doxorubicin using liposomes significantly enhances their intracellular accumulation in hepatocellular carcinoma cells, which is particularly relevant for antitumor activity. By entering the nucleus, doxorubicin induces apoptosis by upregulation of Bax, JNK, p387, and p53. Furthermore, miRNA-101 released from liposomes downregulates the expression of NLK, Rab5A, Mcl-1, EZH2, and STMN1 which are responsible for cancer malignancy. The highest inhibitory effect is observed when miRNA-101- and doxorubicin-loaded liposomes are utilized.²⁰¹

CP is another well-known chemotherapeutic agent applied in the cancer therapy.²⁰² Because of the development of drug resistance, nanoparticles like liposomes have been developed to deliver this drug.^{203,204} MiRNA-1284 is a tumor-suppressor factor enhancing the antitumor activity of CP via downregulation of high mobility group box 1 (HMGB1), inhibiting apoptosis and proliferation.¹⁶³ When suppressing cervical cancer progression, codelivery of miRNA-1284 and CP via liposomes results in significant apoptosis (60%) compared with CP (20%) or miRNA-1284 (12%) alone. By enhancing the time in circulation and reducing clearance, liposomes effectively deliver miRNA-1284 and CP to reduce tumor growth in vivo.²⁰⁵ No univocal plan has been developed to overcome drug resistance, each experiment offering a different strategy. Based on work already performed, codelivery of genes and chemotherapeutic agents using nanocarriers is considered the best option. In addition to their favorable biocompatibility profile and ability to enhance the accumulation of genes and antitumor agents, liposomes are applied to reverse drug resistance. In the next section, we will demonstrate how surface modification of liposomes can improve their profile as nanocarriers for gene delivery and cancer suppression.

TABLE 4 ShRNA-loaded liposomes in cancer therapy.

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modifica- tion/codelivery Gene and/or drug	In vitro/ In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
PEGylated DC-Chol/DOPE cationic liposomes	140 nm	-6.3 mV	-	pDNA- DOPEPEGDSPE Eg5	In vitro In vivo	A2780 cells Female C57BL/6J mice	Ovarian cancer	Lack of immunogenicity off-targeting features of shRNA Effective targeting of cancer cells and downregulation of target gene Transfection of p_shEg5@LS caused up to 87.1% cell death, including apoptosis and necrosis.	154
Liposomes along with microbubbles	-	-	-	Thymidylate synthase	In vivo	SCID mice	Ovarian cancer	High stability Limited toxicity Downregulation of TS gene Combination with paclitaxel promotes antitumor activity and increases mice survival. It showed excellent antitumor activity of 76, 96, and 98% on days 14, 21, and 28, respectively.	161
Liposome combined with focused ultrasound	241.4 nm	10.9 mV	-	NGR peptide Birc5	In vitro In vivo	C6 cells Orthotopic C6 glioma	Glioma	High transfection efficiency Decreasing tumor growth and increasing survival time of tumor mice	163
Liposomes combined with microbubble	-	-	-	Metadherin	In vitro	MCF-7, MCF-10A, and T47D cell lines	Breast cancer	Effective downregulation of metadherin Subsequent decrease in proliferation and migration of cancer cells EMT inhibition Enhanced permeability of cells due to liposome combination with microbubbles	164

(Continues)

TABLE 4 (Continued)

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modification/ codelivery		In vitro/ In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
				Gene and/or drug						
Liposomes	200 nm	15 mV	–	iRGD-PEG ₂₀₀₀ - DSPE eIF3i		In vitro In vivo	Bi6F10 melanoma cells Mouse model of lung metastasis	Melanoma	Inhibiting invasion and metastasis of cancer cells Suppressing lung metastasis of melanoma cells via eIF3i downregulation Treatment with R-LP/shIF3i, which led to decreased expression of eIF3i, resulted in only 6% of Ki67 expression. Conversely, treatment with R-LP/shNC resulted in 46% of Ki67 expression.	165
Folate-targeted cationic liposomes	–	–	–	Thioredoxin 1 Doxorubicin		In vitro	Bel7402 cells	Hepatocellular carcinoma	Strong DNA condensation capacity Surface modification with folic acid enhanced cellular uptake Increasing intracellular accumulation of doxorubicin Downregulation of thioredoxin 1	178
Magnetic cationic liposomes	135– 319.4 nm	+19.8 to +52 mV	–	SATB1 Doxorubicin		In vitro In vivo	MKN-28 cell line Xenograft mouse model	Gastric adeno- carcinoma	Suppressing growth of gastric cancer SATB1 downregulation Delivery of doxorubicin at the tumor site Synergistic impact between doxorubicin and SATB1 On day 15, the tumor volume in mice treated with TSMCL-DOX-shSATB1 was 0.44 ± 0.05 cm ³ .	179
Liposomes	110.3 nm	+18.5 mV	88.9%	PFKFB3 Docetaxel		In vitro In vivo	A549 (CCL-185), H460 (HTB- 177) and HEK293 (CRL- 1573) cells A549 tumor xenograft model in nude mice	Non-small cell lung cancer	Downregulation of PFKFB3 and subsequent induction of apoptosis and cell cycle arrest Downregulation of Cdk2 for cell cycle arrest induction Reducing survival via survivin inhibition Apoptosis induction via caspase-3 upregulation and Bcl-2 downregulation	184

(Continues)

TABLE 4 (Continued)

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modifica- tion/codelivery		In vitro/ In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
				Gene and/or drug						
Chitosan- and hyaluronic acid-enveloped liposomes	105–	–20.2 to	–	CS with a	In vitro	MDA-MB-231	Breast cancer	Smart liposomes sensitive to pH and	186	
	162.3 nm	+33.9 mV		hydrophobic oleic acid tail (CMO) Hase, Survivin	In vivo	cells BALB/c nude mice		GSH Selective targeting of cancer cells overexpressing CD44 due to surface modification with hyaluronic acid Reducing tumor growth via survivin downregulation. The silencing efficiency reached 72.5%.		
pH-sensitive liposomes	193.8 nm	18.47 mV	66.45%	SIRT1 Docetaxel	In vitro	MDA-MB-231 and MCF-7 cells	Breast cancer	Effective codelivery of SIRT1-shRNA and docetaxel Enhancing antitumor activity of docetaxel by threefold Decreasing tumor burden (78%) pH-sensitive SIRT1 downregulation There was a significant reduction in tumor mass (~52% reduction in tumor burden, compared with control).	187	
Liposome microbubbles	–	–	–	Branched polyethylenei- mine Survivin	In vitro	HeLa, HepG2, Ishikawa, MCF-7, and B16-F10 cells	Different cancers	Downregulation of survivin at mRNA and protein levels High transfection efficiency Retarding tumor growth. pSIREN/S3 with LM and USE inhibited Survivin mRNA expression by 82.35 ± 2.84.	188	




FIGURE 5 A comprehensive depiction of L-miR-375/DOX-NPs that work in synergy to combat tumors and reverse the drug resistance mechanism in HCC. (A) liposomal nanocarriers in targeted delivery. The miRNA-375 operates in the cytoplasm while DOX works in the nucleus to suppress cancer progression. (B) Tumor size. (C and D) Growth curves. Reproduced with CC-BY license from Ref. 199, Copyright (2017), Elsevier.

3.4.2 | Surface-modified liposomes

Liposomes can be customized to target cancer cells using specific receptors that are overexpressed on these cells. By identifying these receptors, liposomes can be modified to enhance their selectivity toward cancer cells. Tf is a blood plasma protein that is vital in transporting iron to the cells upon binding to the Tf receptor (TfR). TfR is overexpressed in hepatocellular carcinoma, making it a great target for surface modifications of liposomes.^{206–208} Chemically modified liposomes with Tf as a targeting ligand were used to deliver anti-miRNA-221, which inhibits liver cancer growth by increasing the expression levels of phosphatase and tensin homolog (PTEN) and tissue inhibitors of metalloproteinase 3 (TIMP3).²⁰⁹ In addition to ligand modifications, liposomes can also be modified with various polymers, such as PEG, which have been reported to improve their delivery and pharmacokinetic features.^{210,211} PEGylation enhances liposomes' systemic circulation, which increases their accumulation at the tumor site by providing an EPR effect.¹⁴² Recent advances in the field of targeted drug delivery have led to the development of α -tocopherol-based PEGylated liposomes for the delivery of miRNA-134. The use of α -tocopherol has been found to enhance the antitumor activity of liposomes and provide a synergistic effect by inhibiting P-glycoprotein (P-gp). The delivery of miRNA-134 via liposomes results in the downregulation of Forkhead Box M1 (FOX M1), leading to a subsequent decrease in the proliferation and survival of cancer cells. Additionally, miRNA-134-loaded liposomes have been shown to induce apoptosis in cancer cells, up to 38%.²¹² Liposomes have the advantage of providing targeted delivery of miR-

NAs while displaying high biocompatibility and having minimal adverse effects on erythrocytes.²¹³

Enhancement of transfection efficiency is a crucial aspect of nanocarrier-mediated delivery, and aptamers have demonstrated promise in this regard.²¹⁴ Unlike conventional antibodies, aptamers possess low immunogenicity, high targeting capacity, greater stability, and can be easily synthesized.²¹⁵ This makes them an ideal candidate for enhancing the selectivity of nanocarriers. The overexpression of epithelial cell adhesion molecule (EpCAM) is a hallmark of various cancers, while it maintains normal expression in healthy cells.^{216–218} The EpCAM aptamer can be used to target these cancer cells with higher specificity. To this end, EpCAM aptamer-functionalized cationic liposomes have been developed for miRNA-139-5p delivery. These liposomes have a particle size of 15.3 nm and display a round-shaped structure. Further investigations have revealed that these nanocarriers have a negligible hemolysis rate. Upon delivery, they effectively delivered miRNA-139-5p to the tumor site, leading to a decrease in the growth and invasion of colorectal cancer (Figures 6A–C).²¹⁹

In a separate set of experiments, researchers utilized aptamer AS1411 to modify the surface of liposomes for use in ovarian cancer therapy. The results indicated that miRNA-19b aptamer-functionalized liposomes were effective in reducing cell proliferation and viability in this specific context.²²⁰ This evidence highlights liposomes as a promising candidate for miRNA delivery, which can help limit the progression of cancer. Additionally, when combined with chemotherapeutic agents, liposomes can promote cancer cell sensitivity. The incorporation of miRNAs into liposomes has also been shown to inhibit downstream targets responsible for cancer progression.²²¹




FIGURE 6 The fabrication of NPs and ANPs and in vivo targeting and biodistribution of ANPs. (A) Preparation of nanoparticles. (B) In vivo fluorescence images of xenotransplanted mice after intravenous injection of free DiR, DiR-NPs, and DiR-ANPs for 1, 8, 24, and 48 h. The dashed circles indicate the tumor foci in mice. (C) Tumor sizes. Reproduced with permission from Ref. 219, Copyright (2019), American Chemical Society. (D) Liposomal nanocarriers are efficient vectors for delivering miRNAs and promote cancer suppression. Figure was created with BioRender.com.

The potential of miRNA-loaded liposomes in cancer therapy is comprehensively reviewed in Table 5. Furthermore, Figure 6D offers a schematic representation of miRNA-loaded liposomes and their mechanisms of action in cancer suppression.

3.5 | lncRNA delivery

LncRNAs are ncRNAs with various physiological functions in cells.^{223–225} LncRNAs are more than 200 nucleotides long and do not encode for proteins.^{226–228} RNA polymerase II transcribes lncRNAs without being translated. Increasing evidence has demonstrated that lncRNAs regulate biological events such as apoptosis, proliferation and migration, deregulated in different tumors.^{11,229,230} For this reason, lncRNAs can be considered diagnostic and prognostic tools in cancer setting.^{231–234} To date, a few studies have examined the role of liposomes in lncRNA delivery and have all confirmed the potential of these nanocarriers. Recent work has shown that anti-lncRNA-loaded liposomes can mediate the chemosensitivity of the cervical tumor. Targeted delivery of anti-lncRNA editor of DNA damage checkpoint 1 via liposomes significantly diminishes the progression of the cervical tumor. This antitumor activity benefits oxaliplatin sensitivity (Figures 7A–D).²³⁵

The lncRNA metallothionein 1D pseudogene (MT1DP) is another factor, the expression of which undergoes downregulation in different cancers. It has been shown that enhancing the expression levels of MT1DP is correlated with a decrease in viability and colony formation of the liver tumor.²³⁶ Targeted delivery of lncRNA MT1DP using folate-modified liposomes induces ferroptosis in lung tumor. In this way, MT1DP promotes the stability of miRNA-365a-3p to downregulate the nuclear factor erythroid 2-related factor 2 (Nrf2). Upon inhibition of Nrf2 signaling, ROS levels increase, resulting in ferroptosis and decreased viability of lung cancer cells (Figures 7E–H).²³⁷ Previous work has shown that siRNA-loaded liposomes can promote cancer elimination. Since siRNA is a promising tool in reducing the levels of lncRNAs, siRNA-loaded liposomes have been applied to target lncRNAs in other disease settings.²³⁸ Therefore, this strategy can be applied in future work to target lncRNAs responsible for tumor growth. Liposomes as effective nanocarriers could enhance efficacy in gene silencing.

3.6 | CRISPR/Cas9 delivery

The CRISPR/CRISPR-associated protein (Cas) systems are related to the adaptive immune systems of archaea and

bacteria. In recent years, considerable effort has been spent to make CRISPR applicable to the disease therapy.^{239–241} CRISPR/Cas9 is the most common type of CRISPR system that induces cleavage in double-stranded DNA via Cas9, an endonuclease guided by crRNA.²⁴² Upon DNA cleavage, molecular mechanisms responsible for genome editing, such as nonhomologous end joining (NHEJ) and homology-directed repair pathways, are activated.²⁴³ These mechanisms can lead to end joining, base insertion and deletion or directional mutation using a homologous repair template.^{244–246} Recently, the CRISPR/Cas9 system has been applied to treat various tumor kinds, including mammary, cervical, ovarian, and lung cancers, by targeting signaling networks. In addition to reducing tumor progression, CRISPR/Cas9 system can be applied to elevate drug sensitivity. However, this system suffers from off-targeting effects that could be overcome using vectors.^{247–253} In this section, we discuss the use of liposomes for the targeted delivery of the CRISPR/Cas9 system in cancer treatment.

As mentioned earlier, the CRISPR/Cas9 system is a novel strategy in gene regulation, and because of its ease of use and synthesis, it has been increasingly applied to multiple settings. Off-targeting effects and degradation by enzymes are two important issues limiting its efficiency in gene silencing. It has been reported that encapsulation of the CRISPR/Cas9 system by liposomes protects it from DNase I degradation while providing targeted delivery. Furthermore, liposomes enable controlled release of the CRISPR/Cas9 system, which is important when increasing gene regulation efficiency.²⁵⁴ In previous sections, we have discussed the development of advanced liposomes for the gene delivery.²⁵⁵ Most liposomes are designed based on their response to internal stimuli, the pH being the most important one. To enhance targeted delivery of CRISPR/Cas9, pH-sensitive cationic liposomes have been generated to effectively downregulate HR-HPV16E6/E7 oncogene, leading to apoptosis induction and reducing the proliferation of cervical cancer cells. These liposomes display prolonged time in circulation and display high biocompatibility. Furthermore, intratumoral injection into nude mice significantly decreases tumor growth.²⁵⁶ For all these reasons, they are promising candidates for CRISPR/Cas9 delivery in cervical cancer treatment.

Recently, an effort has been made to use liposome-template hydrogel nanoparticles (LHNPs) for CRISPR/Cas9 delivery. Compared with other types of nanocarriers, such as lipid nanoparticles²⁵⁷ and DNA nano clews,²⁵⁸ LHNPs demonstrate two significant advantages. The first is that LHNPs can provide CRISPR/Cas9 delivery at the protein form, leading to significant increase in efficiency and specificity.²⁵⁹ Second, LHNPs can cross the BBB and deliver the CRISPR/Cas9 system

TABLE 5 MiRNA-loaded liposomes in cancer therapy.

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modification gene and/or drug	In vitro In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
Liposome	117.7–162.5 nm	15.3–52.4 mV	Up to 85%	MiRNA-375 Doxorubicin	In vitro In vivo	HepG2 and SMMC-7721 cells Xenografts		Reducing expression levels of ATG7, YAP1 and AEG-1 Inducing apoptosis and cell cycle arrest (G2/M phase) Activating caspase cascade JNK upregulation Preventing drug resistance development via downregulation of MDR1 expression HCC cells internalized L-miR-375/DOX-NPs.	199
Liposome	119.4–159.8 nm	17.6–43.6 mV	Up to 87%	MiRNA-101 Doxorubicin	In vitro In vivo	Huh7, SMMC-7721 and HepG2 cells Xenograft model of hepatocellular carcinoma		Decreasing colony formation, proliferation and invasion Inducing apoptosis Combination of chemotherapy and gene therapy The expression of Caspase-3 was induced, and the expression of the apoptosis-suppressing gene Bcl-2 was suppressed by miR-101/DOX-L. Additionally, miR-101/DOX-L simultaneously stimulated the expression of Bax, which encodes a dominant inhibitor of the Bcl-2 protein.	201

CD59sp-conjugated liposomes	168.4 nm	16.2 mV	–	MiRNA-1284 Cisplatin	In vitro	HeLa cells		Cancer elimination in a concentration-dependent manner Effective delivery of miRNA-1284 and subsequent downregulation of HMGB1 Prolonging blood circulation Enhancing cytotoxicity of cisplatin against cancer cells Apoptosis induction The combination of CD/LP-miCDDP showed the highest level of apoptosis effect, reaching around 60%.	205
-----------------------------	----------	---------	---	-------------------------	----------	------------	--	--	-----

(Continues)

TABLE 5 (Continued)

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modifica- tion/codelivery gene and/or drug	In vitro/ In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
Tf-targeted liposomes	122.5 nm	−15.74 mV	70%	MiRNA-221	In vitro	HepG2 cells		Higher efficiency compared with nontargeted liposomes	209
				hydrogenated soybean phospholipid (HSPC)/cholesterol (CHOL)/1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-methoxy (polyethylene glycol) (mPEG)	In vivo	Female BALB/c-nu mice		Effective delivery at the tumor site Upregulation of PTEN, P27 and TIMP3 by delivered miRNA-221 for cancer suppression. Tf-RL demonstrated high efficacy in silencing gene expression in HepG2 cells.	
TPGS-based PEGylated liposome	134 nm	15.1 mV	–	MiRNA-134	In vitro	sSCC cell line		Increasing apoptosis (38%) Suppressing cancer cell metastasis Low growth rate Downregulation of FOXM1 by miRNA-134	212
					In vivo	Tumor mice			
Stearylamin liposomes	70–100 nm	−1.1 mV	–	Anti-miRNA-191	In vitro	MCF-7 and ZR-75-1 cells	Breast cancer	Partial toxicity on erythrocytes Suppressing cancer cell growth Apoptosis induction Impairing cancer metastasis Enhancing sensitivity of breast cancer cells to chemotherapeutic agents such as cisplatin and doxorubicin	213
EpCAM aptamer-functionalized cationic liposomes	150.3 nm	37.8 mV	–	EpCAM Apt MiRNA-139-5p	In vitro	HCT116 cells	Colorectal cancer	Selective delivery of miRNA-139-5p to cancer cells due to surface modification with epithelial cell adhesion molecule (EpCAM)	219
					In vivo	Animal model of colorectal cancer		Partial blood hemolysis Suppressing proliferation and metastasis of cancer cells High cellular uptake Decreasing tumor growth in vivo The tumor volume of mice treated with MANP was only increased by 351.8 mm ³ compared with NPs (increased by 2002.1 mm ³)	

(Continues)

TABLE 5 (Continued)

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modification gene and/or drug	In vitro/ In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
Cationic liposomes	120–	Up to	–	MiRNA-145	In vitro	293T cells,	Different	High transfection efficiency High biocompatibility (low cytotoxicity toward normal cells)	221
	600 nm	40 mV				hepatoma cells (HepG2), cervical cancer cells (HeLa), breast adenocarcinoma cells (MCF-7), lung adenocarcinoma cells (A549), human gastric cancer (BGC-823) and human colorectal cancer cells (LoVo)	cancers		
Cationic liposomes	–	–	–	DOTAP/cho MiRNA-101	In vitro	HeLa and Siha cells		High transfection efficiency High biocompatibility Cationic liposomes as candidates for miRNA-101 delivery in cancer treatment	222




FIGURE 7 lncRNA delivery with nanoliposome for cancer gene therapy. (A) Drug administration procedure. (B) Drug administration in mice. (C and D) In vivo antitumor test (C: size of transplanted tumor, D: survival curve). $**p < 0.0001$. Reproduced with CC-BY license from Ref. 235, Copyright (2017), International Journal of Nanomedicine. This is a schematic diagram of the preparation of E/M@FA-LPs and its antitumor effect. (E) Nanoparticle synthesis. (F) TEM images. (G) MTT assay. (H) Migration investigation of tumor cells exposed to liposomes. Reproduced with CC-BY license from Ref. 237, Copyright (2020), Nature Journal.




FIGURE 8 Liposomes for CRISPR/Cas9 delivery and cancer treatment. (A) Exposing tumor cells to liposomes. (B) Apoptosis assay. Reproduced with CC-BY license from,²⁶⁵ Copyright (2017), Oncotarget.

to the brain, making them suitable for the delivery of gene therapy in the setting of brain tumors.^{126,260,261} Due to these advantages, work has been done to use LHNPs for the delivery of CRISPR/Cas9 in glioma treatment. These nanocarriers successfully downregulate polo-like kinase 1 (PLK1) expression to suppress cancer progression.²⁶² Regarding the tumor-promoting role of PLK1 in cancer, significant effort has been made to inhibit this factor. PLK1 activation is responsible for cancer progression and drug resistance, while its downregulation exerts antiproliferative effects.^{263,264} To treat prostate cancer, aptamer-functionalized liposomes containing CRISPR/Cas9 for PLK1 manipulation have been developed. Figure 8A shows the fluorescently tagged CRISPR/Cas9 uptake in the cytoplasm of cells. Liposome

chimeras with A10 aptamer showed the most potent gene silencing effect due to the efficient delivery of CRISPR/Cas9 into LNCap cells. In Figure 8B, apoptosis was observed in LNCap cells due to downregulation of PLK-1. The modification of liposomes by aptamers results in the selective targeting of prostate cancer cells overexpressing prostate-specific membrane antigen (PSMA).²⁶⁵

Another challenge in cancer therapy relates to the fact that cancer cells can stimulate molecular pathways that are responsible for reducing antitumor immunity. Programmed death-1 (PD-1) signaling activation results in central and peripheral T-cell tolerance. Due to the role of PD-1 signaling in reducing T cell proliferation and toxicity against cancer cells, inhibitors have

been developed for effective cancer immunotherapy.^{266–268} The CRISPR/Cas9 system has been applied to regulate PD-1 and ultimately enhance antitumor immunity, suppress tumor growth, and activate receptors beneficial for cancer immunotherapy.^{269,270} Recently, a combination of CRISPR/Cas9-loaded liposomes and dendritic/tumor fusion cells (FCs) has been applied in cancer therapy. The CRISPR/Cas9-loaded liposomes led to the downregulation of PD-1 in T cells this was followed by their activation by FCs. This combination significantly enhanced T cell proliferation, secretion of proinflammation cytokines such as interferon- α (IFN- α), and elimination of HepG2 cells.²⁷¹ This study demonstrated the role of CRISPR/Cas9-loaded liposomes in enhancing antitumor immunity via PD-1 downregulation. More experiments are required to validate the true potential of CRISPR/Cas9-loaded liposomes in cancer suppression and stimulating antitumor immunity (Table 6).

4 | LIPOSOME RELEASE KINETICS

Conducting in vitro release kinetics studies is imperative to better understand the release profile of RNA payloads from liposome-based gene carriers over time. These studies provide critical insights into the kinetics of RNA release, including both the rate and extent of release. Such information is essential in optimizing the design and performance of liposome-mediated RNA delivery systems.²⁷³ To this end, in vitro-release kinetics studies are critical to developing effective gene delivery platforms.²⁷⁴ There are many factors that affect gene release behavior in nanoliposomes.²⁷⁵ The kinetics of gene release in liposomal carriers are significantly influenced by the lipid composition of the carrier. The physicochemical properties of the different lipids present in the carrier can substantially alter the permeability and stability of the liposomal membrane, thereby impacting the rate and mechanism of gene release. Hence, it is imperative to carefully select lipids with appropriate physicochemical properties to optimize gene release kinetics in liposomal carriers.¹⁸ The encapsulation of genes within liposomes can be influenced by the method employed, which can subsequently impact the release kinetics. Techniques such as lipid film hydration, sonication, or extrusion can give rise to variations in cargo loading efficiency and release behavior. It is important to note that the choice of encapsulation method must be made with careful consideration of the desired release profile, as well as the stability and integrity of the encapsulated material.⁵⁴ Surface modifications, such as PEGylation or ligand conjugation, have been shown to impact gene release kinetics and the interaction of liposomes with biological environments. Stealth coatings can

increase circulation time and alter release profiles while targeting ligands can enhance specificity and direct release to specific sites. pH-sensitive lipids incorporated into liposomal membranes enable triggered release in response to changes in pH, such as those encountered in endosomes or lysosomes. The pH-dependent release mechanisms play a crucial role in enhancing the cytoplasmic delivery of genes. The ability to modulate the interaction of liposomes with biological environments enables researchers and clinicians to tailor drug delivery systems to meet specific therapeutic needs.²⁷⁶

Yang et al.²⁷⁷ developed long-circulating and cationic liposomes as a delivery system for siRNA to improve its cellular uptake and inhibitory activity on the expression of VEGF in cancer cells. The efficacy of the cationic liposomes was evaluated by fluorescence-activated cell sorting studies and confocal laser scanning images, which demonstrated the increased uptake of fluorescence-labeled siRNA in cancer cells. These findings suggest that cationic liposomes may serve as a promising platform for the targeted delivery of siRNA in cancer therapy.²⁷⁷

Yang et al.¹³⁹ have created a new siRNA targeting system that merges the qualities of biological and physical siRNA targeting for use in magnetic hyperthermia-triggered release. The system incorporates cell-permeable peptides (CPPs) and magnetic materials. They loaded the siRNA-CPP conjugate in thermal and magnetic dual-sensitive liposomes and tested the release activity, gene silencing efficiency, targeted cellular uptake, in vivo targeted delivery, and in vivo antitumor activity of siRNA-CPPs in vitro. By using magnetic liquid Fe₃O₄, they successfully achieved TML release of thermally triggered siRNA-CPPs in the cell. This research demonstrates that such dual-sensitive vesicles have great potential for delivering siRNA effectively for oncotherapy.¹³⁹

Nahire et al.¹¹¹ developed a system that utilizes pH-triggered echogenicity and content release from liposomes. The system takes advantage of the production of CO₂ gas bubbles when liposomes are incubated in acidic pH buffers, which leads to echogenicity in the liposomes. Structural changes in the liposomes, caused by escaping gas bubbles, facilitate the release of encapsulated contents, with a potential release rate of up to 56%. The researchers further demonstrated that the system's release kinetics could be enhanced by the simultaneous application of diagnostic frequency ultrasound (1 MHz, 5 min), resulting in an 80% release rate. These findings hold the potential to advance the field of drug delivery systems, making it possible for targeted release of encapsulated contents in response to specific stimuli.¹¹¹

The kinetics of gene release from liposomal carriers are crucial in determining the efficiency and specificity of gene delivery for therapeutic purposes. A thorough under-

TABLE 6 CRISPR/Cas-loaded liposomal nanocarriers in cancer therapy.

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Encapsulation efficiency (%)	Surface modifica- tion/codelivery gene and/or drug	In vitro/In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
Cationic liposomes	100–150 nm	+36 mV	–	GFP (green fluorescent protein)	In vitro	HepG2 cells	Hepatocellular carcinoma	Prolonged release Protection against degradation by DNase I High cellular uptake	254
pH-sensitive cationic liposomes	266.8– 452.9 nm	44–76.21 mV	–	HPV	In vitro In vivo	SiHa, Caski and C33A cells Nude mice	Cervical cancer	Suppressing the proliferation of cervical cancer cells Apoptosis induction via HR-HPV16E6/E7 downregulation Long circulation in blood stream pH sensitive and enhancing cellular uptake Reducing tumor growth in vivo	256
Liposome-templated hydrogel nanoparticles			62.8%	PLK1	In vitro In vivo	U87 cells Tumor- bearing mice	Glioma	Effective gene delivery and downregulation of PLK1 in glioma Suppressing tumor growth in vitro and in vivo	262
Aptamer-cationic liposome	150 nm	40 mV	–	PLK1	In vitro In vivo	LNCaP and PC-3 cells Male athymic nude mice	Prostate cancer	Selective targeting of prostate cancer cells overexpressing PSMA due to surface modification with aptamer Significant downregulation in gene expression Silencing capacity confirmed in vitro and in vivo	265

(Continues)

TABLE 6 (Continued)

Nanoarchitecture liposome composition	Particle size (nm)	Zeta potential (mV)	Surface modifica- tion/codelivery gene and/or drug	Encapsulation efficiency (%)	In vitro/In vivo	Cell line/animal model	Tumor	Outcomes and antitumor effects	References
Liposome nanoparticle	-	-	-	-	In vitro In vivo	HepG2 cells and lung adenocar- cinoma cell line A549	Hepatocellular carcinoma	To stimulate T-cell activation in response to DC/tumor FCs and enable T-cell mediated cancer immunotherapy, liposome-encapsulated CRISPR/Cas9 genome editing technology proved effective in knocking out the PD-1 gene in T-cells.	267
Stealth liposomes	-	-	E7	-	In vitro In vivo	CasKi (HPV 16 +ve, passage number 6), C33A (HPV -ve, passage 12), HeLa (passage number 23), and Jurkat cell lines Immunocomp C57BL/6J mice	Cervical cancer	Lack of toxicity on spleen and liver Downregulation of E7 by CRISPR-loaded liposomes does not result in immunogenic cell death	272

standing of the factors influencing release behavior and the use of appropriate experimental techniques can facilitate the design of optimized liposomal formulations that enable precise and effective gene delivery. To summarize, the elucidation of gene release kinetics from liposomes has immense promise for advancing gene therapy strategies and addressing challenges associated with nucleic acid delivery in biomedical research and clinical practice.

5 | LIPOSOMES AND DETERMINING FACTORS

Although previous sections demonstrate the efficacy of liposomes in cancer gene therapy, some key factors should be considered in future work aimed at developing effective liposomal nanocarriers for cancer gene therapy. The lipid composition of liposomes affects their capacity to deliver genes. For example, it has been reported that upon injection of siRNA-loaded cationic liposomes, lipids with amine head group, linker arm, and length of alkyl groups affect the biodistribution of siRNA.²⁷⁸ Furthermore, to induce the fusion process, aromatic molecules' conical shape and presence are important. Noteworthy, the lipid composition and the formation of the complex with genetic tools affect liposome size and zeta potential, resulting in changes in the biodistribution.²⁷⁹ Liposomes with a particle size of 5–50 nm are excreted through the urine or accumulate in the liver. However, as the size increases further, penetration into cancer cells decreases, thus limiting their cellular uptake and transfection efficiency.²⁸⁰ Hence, the impact of the DNA complex on the liposome size should be considered. In addition to the size, surface charge or zeta potential is another factor impacting the functionality of liposomes. After binding to genetic tools such as siRNA, the zeta potential of liposomes decreases due to their negative charge. Furthermore, cationic liposomes deliver genetic tools that cause immune system activation and aggregation (due to low electrostatic repulsion).²⁸¹ Finally, the protein corona is another factor that affects liposome behavior. Following in vivo administration, several proteins are absorbed onto the surface of nanoparticles, constituting the biological profile of a certain nanocarrier.²⁸² The body sees and interacts with the protein corona instead of synthetic surface of a nanocarrier. Therefore, protein corona affects the in vivo fate of a nanoparticle.^{283,284} Liposomes have been reported to decrease in size after contacting the plasma. The lipid composition determines the interaction of liposomes with the plasma proteins. Liposomes containing 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) interact with vitronectin, while liposomes containing DOPE specifically interact with apolipoproteins.²⁸⁵ Such interactions greatly

affect the fate of nanoparticles. For example, liposomes demonstrate high cellular uptake by hepatocytes when interacting with apolipoprotein B and E.²⁸⁶ Overall, size, zeta potential, protein corona, and lipid composition determine the biodistribution and fate of liposomes. These parameters should be carefully determined before using liposomal nanocarriers to deliver genetic tools.

Incorporating histopathology in studies concerning liposomes or modified liposomes can provide significant insights into the potential side effects and tissue responses related to their use. Histopathological analysis facilitates the examination of cellular and tissue alterations, such as inflammation, necrosis, fibrosis, and other pathological changes, which may occur following liposome administration. This approach is crucial to researchers as it provides essential information regarding the safety profile and efficacy of liposomes and modified liposomes, thus enhancing their translational potential. Histopathological findings are a crucial aspect of research on the long-term effects of liposome exposure. These findings provide insights into potential toxicity and tissue remodeling. By correlating histopathological data with other endpoints, such as biochemical analyses and functional assessments, researchers can gain a comprehensive understanding of the safety profile and therapeutic efficacy of liposomes. This approach enables a more thorough evaluation of liposomes.

Zhu et al.²⁸⁷ utilized peptide-based cationic liposomes to conduct histopathology tests on mice in order to investigate any potential tissue damage or inflammation. The mice were inspected three times daily, and the researchers observed no discernible histopathological alterations in kidney and spleen tissue sections following CDO14 and DOTAP injection.

Zhang et al.²⁸⁸ utilized liposome technology to target M2 macrophages in their gene therapy approach aimed at developing siRNA-loaded (siIKK β -ML) liposomes that inhibit kappa B kinase β (IKK β). Upon examining the results of their experiment, which aimed to effectively reprogram the M1 phenotype and prevent proangiogenic functions, it was observed that when compared with the control group, there were no significant abnormalities in the retinal structure for either the intravitreal injection of siIKK β -ML or free siIKK β , as determined through a combination of optical coherence tomography and histopathological examination.

Quin et al.²⁸⁹ have developed liposomes that are modified with perfluorooctyl bromide (PFOB@Lipo) to facilitate the loading of oxygen and its targeted delivery to tumor sites. With this approach, they aim to make it possible to alleviate the hypoxic conditions common in tumors. Then, to inhibit tumor progression, PAR-Lipo was applied to mediate high-efficiency delivery of the suppressor gene pTP53. Researchers used the TUNEL

assay and hematoxylin and eosin to evaluate cell apoptosis. Results indicate that the combination of apoptotic cells reached maximum levels. The modified PAR-Lipo/pTP53 generated through this method consistently exhibited effectiveness in destroying tumor cells. Tissue histopathology analyses were conducted to compare the groups, and no significant abnormalities were observed in comparison with both the control group and other groups, revealing good biocompatibility of the therapeutic procedure. Ultimately, they found that O₂@PL was capable of carrying oxygen to eliminate hypoxia in the tumor, thereby enhancing its antitumor ability in gene therapy.

Arora et al.²⁹⁰ used a modified liposome approach to treat Alzheimer's disease, producing ApoE2-encoding plasmid DNA (pApoE2). The liposomes aim to a special brain-targeted glucose transporter-1 (glut-1). The liposomes underwent surface functionalization through the incorporation of a glut-1 targeting ligand mannose and a CPP. The purpose of this modification was to enhance the liposomes ability to target the brain and improve their cellular internalization. It was evaluated by histopathological analysis of tissues and compared with saline control for its biocompatibility and safety. The analysis revealed that there were no signs of abnormality in the morphology, inflammatory cell infiltration or necrosis in any of the organ tissues examined. In addition, there were no irregularly shaped nuclei or any other abnormalities observed in the brain tissues of the treated mice. The liver tissue showed no signs of ballooning or inflammation, the heart tissue showed no deterioration of muscle fibers or myofibril loss, and no signs of pulmonary fibrosis were found in the lungs. According to the study, the dual-functionalized liposomes demonstrate safety when used in living organisms. No undesirable effects, including cell death or inflammation, were observed in tissue samples collected from animals receiving the formulations. This indicates that these liposomes hold significant potential as a delivery vehicle for gene therapy in the treatment of Alzheimer's disease.

Incorporating histopathological evaluation in preclinical and clinical studies of liposomes or modified liposomes is a crucial step in comprehensively assessing their safety profiles and understanding potential side effects. Through the elucidation of tissue-level responses and mechanisms of action, histopathology plays a vital role in the rational design and optimization of liposomal drug delivery systems for therapeutic applications. By providing insights into the structural and functional changes associated with liposome administration, histopathological analyses contribute to a more comprehensive understanding of the safety and efficacy of these systems. Therefore, researchers and clinicians should incorporate histopathological eval-

uation as an integral component of their studies to optimize the therapeutic potential of liposomal drug delivery systems.

6 | PRECLINICAL AND CLINICAL STUDIES: PROGRESS AND OBSTACLES

To date, experiments confirmed the role of liposomes in cancer gene therapy. In vitro experiments demonstrated that liposomal nanocarriers containing siRNA can diminish the expression pattern of target genes and therefore reduce cancer progression. In vivo experiments showed siRNA protection by liposomes, which provide targeted delivery at the tumor site and high cellular uptake. These features are vital for suppressing cancer growth and metastasis in vivo. Due to the progress in bioinformatics, the molecular pathways responsible for cancer progression have been identified and targeted by gene-loaded liposomes. Furthermore, upon recognition of receptors on the cell surface, related antibodies or ligands can be utilized to enhance the selectivity of liposomes toward cancer cells. Surface modification of liposomes has been deployed in preclinical studies. Advanced liposomes sensitive to pH, light and redox have been developed to optimize the internalization of liposomes into the tumor tissue. Finally, the codelivery of antitumor compounds and genetic tools by liposomes has been developed, supporting the role of liposomes in cancer gene therapy. However, the clinical application of liposomes requires further optimization in their synthesis. The large production of liposomes represents one potential problem. There should be a novel and cost-effective way to synthesize liposomes at the scale needed for clinical application. Another caveat is the biocompatibility of gene-loaded liposomes. It was reported that by enhancing the dose of liposomes, there is a concomitant increase in their side effects. The siRNA-loaded cationic liposomes demonstrate partial toxicity at low doses. However, enhancing their concentration results in pulmonary inflammation and liver injury. This is mediated by the release of proinflammatory cytokines such as TNF- α and IL-6 and decreased anti-inflammatory cytokines such as IL-10.²⁸⁷ As high doses of liposomes should be applied in the treatment of cancer patients, the question remains as to how such concentration-dependent toxicity could be overcome. These concerns should be addressed before commercialization and clinical application. The clinical studies in Table 7 represent efforts to explore the potential of liposome-based gene delivery systems for cancer gene therapy. These studies evaluate the safety and effectiveness of liposomal vectors in delivering therapeutic genes to tumor cells, contributing to developing new treatment strategies for cancer patients.

TABLE 7 Clinical trials of lipoplex-based delivery systems for cancer treatment.

Identifier	Carrier components	gene/drug	Disease	Phase (start year)	Sponsors	Purpose
NCT03323398	Not reported	mRNA encoding human OX40L	Lymphoma	I/II (2017)	ModernaTX, Inc. (Cambridge, MA, USA)	The clinical study evaluates the safety and tolerability of escalating doses of mRNA-2416 alone and in combination with fixed administered doses of durvalumab, as well as the objective response rate (ORR) of mRNA in participants with relapsed/refractory solid tumor malignancies or lymphoma.
NCT02736565	DOTAP:Chol	Pbi-shRNA™ EWS/FLI1 Type 1	Ewing's sarcoma	I (2016)	Gradalis, Inc. (New York, NY, USA)	This clinical trial aims to determine the maximum tolerated dose and safety of pbi-shRNATM EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
NCT01808638	AtuFECT01-DPhyPE/DSPE-PEG-2000	PKN3 siRNA	Pancreatic cancer	I/II (2013)	Silence Therapeutics	The study aims to assess a novel treatment approach for advanced pancreatic cancer. It will use a new investigational drug called Atu027 in combination with the standard chemotherapeutic drug gemcitabine to enhance gemcitabine's antitumor activity.
NCT01505153	DOTAP/Chol	bi-shRNA-stathmin 1 pDNA	Solid tumors	I (2004)	University of Pittsburgh	This is a safety trial of pbi-shRNA™STMN1 lipoplex administered by intratumoral injection.
NCT03338777	DMRIE/DOPE	(HSTK, cIFNβ, hIL-2, hGM-CSF) pDNA	Melanoma	I (2017)	Hospital Italiano de Buenos Aires	This clinical trial protocol aims to assess the safety of combined genetic and immunotherapy in humans.
NCT01591356	DOPC	EphA2 siRNA	Advanced malignant solid neoplasm	I (2012)	M.D. Anderson Cancer Center (Houston, TX, USA)	This clinical trial aims to assess the safety and determine the optimal dosage of EphA2 siRNA in the treatment of patients with advanced or recurrent solid tumors that have metastasized to other parts of the body and are usually untreatable or cannot be controlled with available therapies.

Data source, ClinicalTrials.gov website.

7 | CONCLUSIONS AND REMARKS

Nanoliposome-based cancer gene therapy represents a promising approach to address the limitations of traditional cancer treatments. The multifaceted nature of nanoliposomes allows for precise control over drug delivery, enabling targeted and efficient delivery of therapeutic agents to tumor sites while minimizing systemic toxicity. However, despite the considerable progress made in this field, several critical challenges remain to be addressed to facilitate the clinical translation of nanoliposome-based therapies. One such challenge is the optimization of nanoliposome design to improve stability, specificity, and payload capacity. Advances in lipid composition, surface modifications, and targeting ligands hold the potential to enhance the therapeutic efficacy of nanoliposomes and overcome existing limitations.

Moreover, the safety profile of nanoliposome-based therapies must be thoroughly evaluated to ensure their clinical applicability. Immunogenicity, long-term toxicity, and potential adverse effects on healthy tissues are essential considerations that need to be addressed through comprehensive preclinical studies and clinical trials. Furthermore, the development of innovative strategies to mitigate immunogenicity and enhance the biocompatibility of nanoliposomes will be essential for their widespread adoption in clinical practice.

In addition to addressing safety concerns, future research efforts should focus on harnessing the synergistic effects of codelivering multiple therapeutic agents using nanoliposomes. Combination therapies, incorporating gene constructs, chemotherapeutic drugs, and immunomodulatory agents, have the potential to significantly enhance therapeutic outcomes and overcome treatment resistance in cancer patients. Furthermore, the integration of advanced gene editing technologies, such as CRISPR/Cas9, offers exciting opportunities for precise targeting and modulation of cancer-related genes, paving the way for personalized and tailored treatments.

Overall, nanoliposome-based cancer gene therapy holds immense promise for revolutionizing cancer treatment paradigms. By addressing existing challenges and embracing emerging technologies, nanoliposomes have the potential to transform the landscape of cancer therapy and improve patient outcomes. Continued collaboration between researchers, clinicians, and industry stakeholders is essential to drive innovation, advance clinical development, and ultimately bring nanoliposome-based therapies to the forefront of cancer treatment. Through concerted efforts, nanoliposomes have the potential to fulfill their promise as a powerful tool in the fight against cancer, offering hope to patients and their families worldwide.

AUTHOR CONTRIBUTIONS

Writing—original draft: Safiye Nur Yildiz, Maliheh Entezari, Mahshid Deldar Abad Paskeh, Sepideh Mirzaei, Alireza Kalbasi, Amirhossein Zabolian, Farid Hashemi, Kiavash Hushmandi, Mehrdad Hashemi, Mehdi Raei, and Mohammad Ali Sheikh Beig Goharrizi. *Visualization:* Safiye Nur Yildiz and Yavuz Nuri Ertas. *Writing—reviewing:* Amir Reza Aref, Ali Zarrabi, Jun Ren, Gorka Orive, Navid Rabiee, and Yavuz Nuri Ertas. *Editing and supervision:* Yavuz Nuri Ertas. All the authors have read and approved the final version of the manuscript.

ACKNOWLEDGMENTS

This study was supported by Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, (118C346).

CONFLICT OF INTEREST STATEMENT

Author Amir Reza Aref is an employee of Xsphaera Biosciences, Inc. Author Gorka Orive is an employee of Bioaraba, NanoBioCel Research Group. Other authors have no interest to declare.

DATA AVAILABILITY STATEMENT

Not applicable.

ETHICS STATEMENT

Not applicable.

ORCID

Safiye Nur Yildiz  <https://orcid.org/0009-0008-4896-5553>

Alireza Kalbasi  <https://orcid.org/0000-0002-6657-4950>

Yavuz Nuri Ertas  <https://orcid.org/0000-0002-6791-7484>

REFERENCES

1. Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. *Gene*. 2013;525(2):162-169.
2. Ashrafizadeh M, Zarrabi A, Bigam A, et al. (Nano)platforms in breast cancer therapy: drug/gene delivery, advanced nanocarriers and immunotherapy. *Med Res Rev*. 2023;43(6):2115-2176.
3. Karimi K, Mojtavavi S, Tehrany PM, et al. Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: versatile bio-platform with theranostic application. *Int J Biol Macromol*. 2023;242:124935.
4. Yaray K, Norbakhsh A, Rashidzadeh H, et al. Chemoradiation therapy of 4T1 cancer cells with methotrexate conjugated platinum nanoparticles under X-Ray irradiation. *Inorg Chem Commun*. 2023;150:110457.
5. Taheriazam A, Abad GGY, Hajimazdarany S, et al. Graphene oxide nanoarchitectures in cancer biology: nano-modulators of autophagy and apoptosis. *J Control Release*. 2023;354:503-522.
6. Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. *Nature*. 2004;427(6977):779-781.
7. Hashemi M, Hajimazdarany S, Mohan CD, et al. Long non-coding RNA/epithelial-mesenchymal transition axis in human

- cancers: tumorigenesis, chemoresistance, and radioresistance. *Pharmacol Res.* 2022;186:106535.
8. Almajidi YQ, Kadhim MM, Alsaikhan F, et al. Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. *Environ Res.* 2023;227:115722.
 9. Mirzaei S, Gholami MH, Hashemi F, et al. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: approaching to a new era of cancer chemotherapy. *Life Sci.* 2021;277:119430.
 10. Delfi M, Sartorius R, Ashrafzadeh M, et al. Self-assembled peptide and protein nanostructures for anti-cancer therapy: targeted delivery, stimuli-responsive devices and immunotherapy. *Nano Today.* 2021;38:101119.
 11. Mirzaei S, Zarrabi A, Hashemi F, et al. Regulation of Nuclear Factor-KappaB (NF- κ B) signaling pathway by non-coding RNAs in cancer: inhibiting or promoting carcinogenesis? *Cancer Lett.* 2021;509:63-80.
 12. Zhang W, Mehta A, Tong Z, Esser L, Voelcker NH. Development of polymeric nanoparticles for blood-brain barrier transfer—strategies and challenges. *Adv Sci.* 2021;8:2003937.
 13. Ashrafzadeh M, Zarrabi A, Hushmandi K, et al. Progress in natural compounds/siRNA co-delivery employing nanovehicles for cancer therapy. *ACS Comb Sci.* 2020;22(12):669-700.
 14. Ashrafzadeh M, Hushmandi K, Rahmani Moghadam E, et al. Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer. *Bioeng.* 2020;7(3):91.
 15. Mohammadinejad R, Dehshahri A, Sagar Madamsetty V, et al. In vivo gene delivery mediated by non-viral vectors for cancer therapy. *J Control Release.* 2020;325:249-275.
 16. Ashrafzadeh M, Zarrabi A, Karimi-Maleh H, et al. (Nano) platforms in bladder cancer therapy: challenges and opportunities. *Bioeng Transl Med.* 2023;8(1):e10353.
 17. Yu Y, Gao Y, He L, et al. Biomaterial-based gene therapy. *MedComm.* 2023;4(3):e259.
 18. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. *Adv Drug Deliv Rev.* 2013;65(1):36-48.
 19. Accardo A, Mannucci S, Nicolato E, et al. Easy formulation of liposomal doxorubicin modified with a bombesin peptide analogue for selective targeting of GRP receptors overexpressed by cancer cells. *Drug Deliv Transl Res.* 2019;9(1):215-226.
 20. Aronson MR, Medina SH, Mitchell MJ. Peptide functionalized liposomes for receptor targeted cancer therapy. *APL Bioeng.* 2021;5(1):011501.
 21. Chen W, Goldys EM, Deng W. Light-induced liposomes for cancer therapeutics. *Prog Lipid Res.* 2020;79:101052.
 22. Watts A. Membrane structure and dynamics. *Curr Opin Cell Biol.* 1989;1(4):691-700.
 23. Coderch L, Fonollosa J, De Pera M, Estelrich J, De La Maza A, Parra J. Influence of cholesterol on liposome fluidity by EPR: relationship with percutaneous absorption. *J Control Release.* 2000;68(1):85-95.
 24. Khan AA, Allemailem KS, Almatroodi SA, Almatroudi A, Rahmani AH. Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. *3 Biotech.* 2020;10(4):1-15.
 25. Sakamoto JH, van de Ven AL, Godin B, et al. Enabling individualized therapy through nanotechnology. *Pharmacol Res.* 2010;62(2):57-89.
 26. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. *Curr Drug Deliv.* 2007;4(4):297-305.
 27. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. *Trends Pharmacol Sci.* 2009;30(11):592-599.
 28. Rideau E, Dimova R, Schwille P, Wurm FR, Landfester K. Liposomes and polymersomes: a comparative review towards cell mimicking. *Chem Soc Rev.* 2018;47(23):8572-8610.
 29. Szoka Jr F, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). *Annu Rev Biophys Bioeng.* 1980;9(1):467-508.
 30. Pawar PV, Gohil SV, Jain JP, Kumar N. Functionalized polymersomes for biomedical applications. *Polym Chem.* 2013;4(11):3160-3176.
 31. Walde P, Cosentino K, Engel H, Stano P. Giant vesicles: preparations and applications. *ChemBioChem.* 2010;11(7):848-865.
 32. Villalba A, Rodriguez-Fernandez S, Ampudia RM, et al. Pre-clinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes. *Artif Cells Nanomed Biotechnol.* 2020;48(1):77-83.
 33. Xue L, Wang D, Zhang X, Xu S, Zhang N. Targeted and triple therapy-based liposomes for enhanced treatment of rheumatoid arthritis. *Int J Pharm.* 2020;586:119642.
 34. Li J, Ding F, Qian X, et al. Anti-inflammatory cytokine IL10 loaded cRGD liposomes for the targeted treatment of atherosclerosis. *J Microencapsulation.* 2020:1-19.
 35. Kong L, Li XT, Ni YN, et al. Transferrin-modified osthole PEGylated liposomes travel the blood-brain barrier and mitigate Alzheimer's disease-related pathology in APP/PS-1 mice. *Int J Nanomed.* 2020;15:2841-2858.
 36. Kashyap D, Tuli HS, Yerer MB, et al. Natural product-based nanoformulations for cancer therapy: opportunities and challenges. *Semin Cancer Biol.* 2021;69:5-23.
 37. Shanmugam MK, Warriar S, Kumar AP, Sethi G, Arfuso F. Potential role of natural compounds as anti-angiogenic agents in cancer. *Curr Vasc Pharmacol.* 2017;15(6):503-519.
 38. Cano ME, Lesur D, Bincoletto V, et al. Synthesis of defined oligohyaluronates-decorated liposomes and interaction with lung cancer cells. *Carbohydr Polym.* 2020;248:116798.
 39. Tang B, Peng Y, Yue Q, et al. Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer. *Eur J Med Chem.* 2020;193:112204.
 40. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. *Nat Rev Drug Discov.* 2005;4(2):145-160.
 41. Li C, Deng Y. A novel method for the preparation of liposomes: freeze drying of monophasic solutions. *J Pharm Sci.* 2004;93(6):1403-1414.
 42. Juan-Colás J, Dresser L, Morris K, et al. The mechanism of vesicle solubilization by the detergent sodium dodecyl sulfate. *Langmuir.* 2020;36(39):11499-11507.
 43. Gouda A, Sakr OS, Nasr M, Sammour O. Ethanol injection technique for liposomes formulation: an insight into development, influencing factors, challenges and applications. *J Drug Deliv Sci Technol.* 2021;61:102174.
 44. Shi N-Q, Qi X-R. Preparation of drug liposomes by reverse-phase evaporation. *Liposome-Based Drug Deliv Syst.* 2021:37-46.

45. Wang G, Yang Y, Yi D, et al. Eudragit S100 prepared pH-responsive liposomes-loaded betulinic acid against colorectal cancer in vitro and in vivo. *J Liposome Res.* 2022;32(3):250-264.
46. Carugo D, Bottaro E, Owen J, Stride E, Nastruzzi C. Liposome production by microfluidics: potential and limiting factors. *Sci Rep.* 2016;6(1):25876.
47. Jaafar-Maalej C, Charcosset C, Fessi H. A new method for liposome preparation using a membrane contactor. *J Liposome Res.* 2011;21(3):213-220.
48. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. *Front Pharmacol.* 2015;6:286.
49. Tarahovsky YS, Koynova R, MacDonald RC. DNA release from lipoplexes by anionic lipids: correlation with lipid mesomorphism, interfacial curvature, and membrane fusion. *Biophys J.* 2004;87(2):1054-1064.
50. Wang Y, Zhang R, Tang L, Yang L. Nonviral delivery systems of mRNA vaccines for cancer gene therapy. *Pharmaceutics.* 2022;14(3):512.
51. Zhang R, Tang L, Tian Y, et al. DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine. *J Control Release.* 2020;328:210-221.
52. Nosova A, Koloskova O, Nikonova A, et al. Diversity of PEGylation methods of liposomes and their influence on RNA delivery. *MedChemComm.* 2019;10(3):369-377.
53. Yu W-Y, Zhang N. Surface modification of nanocarriers for cancer therapy. *Curr Nanosci.* 2009;5(2):123-134.
54. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. *Nano-Enabled Med Appl.* 2020:61-91.
55. Das SK. Drug delivery: principles and applications. *Am J Pharm Educ.* 2006;70(4):94.
56. Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. *Nat Rev Drug Discov.* 2017;16(3):181-202.
57. Subhan MA, Attia SA, Torchilin VP. Advances in siRNA delivery strategies for the treatment of MDR cancer. *Life Sci.* 2021;274:119337.
58. Roberts TC, Ezzat K, Andaloussi SE, Weinberg MS. Synthetic siRNA delivery: progress and prospects. *SiRNA Deliv Methods.* 2016;1364:291-310.
59. Supe S, Upadhy A, Singh K. Role of small interfering RNA (siRNA) in targeting ocular neovascularization: a review. *Exp Eye Res.* 2020;202:108329.
60. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. *Trends Biotechnol.* 2010;28(11):570-579.
61. Najafi S, Tan SC, Raee P, et al. Gene regulation by antisense transcription: a focus on neurological and cancer diseases. *Biomed Pharmacother.* 2022;145:112265.
62. Subhan MA, Torchilin V. siRNA based drug design, quality, delivery and clinical translation. *Nanomed Nanotechnol Biol Med.* 2020;29:102239.
63. Paskeh MDA, Mehrabi A, Gholami MH, et al. EZH2 as a new therapeutic target in brain tumors: molecular landscape, therapeutic targeting and future prospects. *Biomed Pharmacother.* 2022;146:112532.
64. Alshehri A, Grabowska A, Stolnik S. Pathways of cellular internalisation of liposomes delivered siRNA and effects on siRNA engagement with target mRNA and silencing in cancer cells. *Sci Rep.* 2018;8(1):3748.
65. Loh CY, Arya A, Naema AF, Wong WF, Sethi G, Looi CY. Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: functions and therapeutic implication. *Front Oncol.* 2019;9:48.
66. Lee JH, Kim C, Sethi G, Ahn KS. Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel. *Oncotarget.* 2015;6(8):6386-6405.
67. Kim C, Cho SK, Kapoor S, et al. β -Caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase. *Mol Carcinog.* 2014;53(10):793-806.
68. Jung YY, Ha IJ, Um J-Y, Sethi G, Ahn KS. Fangchinoline diminishes STAT3 activation by stimulating oxidative stress and targeting SHP-1 protein in multiple myeloma model. *J Adv Res.* 2021;35:245-257.
69. Lee JH, Mohan CD, Deivasigamani A, et al. Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma. *J Adv Res.* 2020;26:83-94.
70. Jung YY, Ko JH, Um JY, et al. LDL cholesterol promotes the proliferation of prostate and pancreatic cancer cells by activating the STAT3 pathway. *J Cell Physiol.* 2020;236(7):5253-5264.
71. Garg M, Shanmugam MK, Bhardwaj V, et al. The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. *Med Res Rev.* 2020.
72. Jose A, Labala S, Venuganti VV. Co-delivery of curcumin and STAT3 siRNA using deformable cationic liposomes to treat skin cancer. *J Drug Target.* 2017;25(4):330-341.
73. Jose A, Labala S, Ninave KM, Gade SK, Venuganti VVK. Effective skin cancer treatment by topical co-delivery of curcumin and STAT3 siRNA using cationic liposomes. *AAPS Pharm Sci Technol.* 2018;19(1):166-175.
74. Hwang ST, Kim C, Lee JH, et al. Cycloastragenol can negate constitutive STAT3 activation and promote paclitaxel-induced apoptosis in human gastric cancer cells. *Phytomedicine.* 2019;59:152907.
75. Mahabady MK, Mirzaei S, Saebfar H, et al. Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: mechanisms of initiation, progression, and drug sensitivity. *J Cell Physiol.* 2022;237(5):2309-2344.
76. Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: role of microRNAs and upstream mediators. *Cell Signal.* 2020;78:109871.
77. Wei W, Lv PP, Chen XM, et al. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. *Biomaterials.* 2013;34(15):3912-3923.
78. Sun X, Chen Y, Zhao H, et al. Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma. *Drug Deliv.* 2018;25(1):1718-1727.

79. Yang Y, Yang Y, Yang J, Zhao X, Wei X. Tumor microenvironment in ovarian cancer: function and therapeutic strategy. *Front Cell Dev Biol.* 2020;8:758.
80. Sun X, Lv X, Yan Y, et al. Hypoxia-mediated cancer stem cell resistance and targeted therapy. *Biomed Pharmacother.* 2020;130:110623.
81. Saxena K, Jolly MK, Balamurugan K. Hypoxia, partial EMT and collective migration: emerging culprits in metastasis. *Transl Oncol.* 2020;13(11):100845.
82. Guan J, Sun J, Sun F, et al. Hypoxia-induced tumor cell resistance is overcome by synergistic GAPDH-siRNA and chemotherapy co-delivered by long-circulating and cationic-interior liposomes. *Nanoscale.* 2017;9(26):9190-9201.
83. Kong Y, Li Y, Luo Y, et al. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. *Mol Cancer.* 2020;19(1):82.
84. Xie M, Yu T, Jing X, et al. Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation. *Mol Cancer.* 2020;19(1):112.
85. Jia LY, Shanmugam MK, Sethi G, Bishayee A. Potential role of targeted therapies in the treatment of triple-negative breast cancer. *Anticancer Drugs.* 2016;27(3):147-155.
86. Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. *Biomaterials.* 2014;35(19):5226-5239.
87. Lu Z, Pang T, Yin X, et al. Delivery of TSPAN1 siRNA by novel Th17 targeted cationic liposomes for gastric cancer intervention. *J Pharm Sci.* 2020;109(9):2854-2860.
88. Chen J, Yu Z, Chen H, Gao J, Liang W. Transfection efficiency and intracellular fate of polycation liposomes combined with protamine. *Biomaterials.* 2011;32(5):1412-1418.
89. Takakura Y, Nishikawa M, Yamashita F, Hashida M. Influence of physicochemical properties on pharmacokinetics of non-viral vectors for gene delivery. *J Drug Target.* 2002;10(2):99-104.
90. Lee J, Ahn HJ. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy. *Biochem Biophys Res Commun.* 2018;503(3):1716-1722.
91. Levine RM, Dinh CV, Harris MA, Kokkoli E. Targeting HPV-infected cervical cancer cells with PEGylated liposomes encapsulating siRNA and the role of siRNA complexation with polyethylenimine. *Bioeng Transl Med.* 2016;1(2):168-180.
92. Verhoef JJ, Anchordoquy TJ. Questioning the use of PEGylation for drug delivery. *Drug Deliv Transl Res.* 2013;3(6):499-503.
93. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. *J Control Release.* 2007;122(3):349-355.
94. Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. *J Control Release.* 2013;172(1):38-47.
95. Mima Y, Hashimoto Y, Shimizu T, Kiwada H, Ishida T. Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein. *Mol Pharm.* 2015;12(7):2429-2435.
96. Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* 2015;7(5):655-677.
97. Godbey WT, Wu KK, Hirasaki GJ, Mikos AG. Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency. *Gene Ther.* 1999;6(8):1380-1388.
98. Sonawane ND, Szoka FC Jr, Verkman AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. *J Biol Chem.* 2003;278(45):44826-44831.
99. Höbel S, Aigner A. Polyethylenimines for siRNA and miRNA delivery in vivo. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* 2013;5(5):484-501.
100. Li T, Ashrafzadeh M, Shang Y, Nuri Ertas Y, Orive G. Chitosan-functionalized bioplatfroms and hydrogels in breast cancer: immunotherapy, phototherapy and clinical perspectives. *Drug Discov Today.* 2024;29(1):103851.
101. Nosrati H, Salehiabar M, Charimi J, et al. Enhanced in vivo radiotherapy of breast cancer using gadolinium oxide and gold hybrid nanoparticles. *ACS Appl Bio Mater.* 2023;6(2):784-792.
102. Rashidzadeh H, Seidi F, Ghaffarlou M, et al. Preparation of alginate coated Pt nanoparticle for radiosensitization of breast cancer tumor. *Int J Biol Macromol.* 2023;233:123273.
103. Salehiabar M, Ghaffarlou M, Mohammadi A, et al. Targeted CuFe₂O₄ hybrid nanoradiosensitizers for synchronous chemoradiotherapy. *J Control Release.* 2023;353:850-863.
104. Ertas YN, Abedi Dorcheh K, Akbari A, Jabbari E. Nanoparticles for targeted drug delivery to cancer stem cells: a review of recent advances. *Nanomaterials.* 2021;11(7):1755.
105. Yaray K, Rashidzadeh H, Mozafari F, et al. CuFe₂O₄ decorated with BSA as a potential nanoradioenhancer for enhanced X-ray radiation therapy of brain tumor. *Chem Pap.* 2023;1-10.
106. Colak B, Ertas YN. Implantable, 3D-printed alginate scaffolds with bismuth sulfide nanoparticles for the treatment of local breast cancer via enhanced radiotherapy. *ACS Appl Mater Interfaces.* 2024;16(13):15718-15729.
107. Zhou L, Cheng R, Tao H, et al. Endosomal pH-activatable poly(ethylene oxide)-graft-doxorubicin prodrugs: synthesis, drug release, and biodistribution in tumor-bearing mice. *Biomacromolecules.* 2011;12(5):1460-1467.
108. Sako M, Song F, Okamoto A, et al. Key determinants of siRNA delivery mediated by unique pH-responsive lipid-based liposomes. *Int J Pharm.* 2019;569:118606.
109. Yao Y, Wang T, Liu Y, Zhang N. Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma. *Artif Cells Nanomed Biotechnol.* 2019;47(1):1374-1383.
110. Zang X, Ding H, Zhao X, et al. Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA. *Int J Nanomed.* 2016;11:3951-3967.
111. Nahire R, Hossain R, Patel R, et al. pH-triggered echogenicity and contents release from liposomes. *Mol Pharm.* 2014;11(11):4059-4068.
112. Auguste DT, Furman K, Wong A, et al. Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. *J Control Release.* 2008;130(3):266-274.
113. Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. *J Nutr.* 2004;134(3):489-492.

114. Kim C, Lee SG, Yang WM, et al. Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model. *Cancer Lett.* 2018;431:123-141.
115. Guo X, Cheng Y, Zhao X, Luo Y, Chen J, Yuan WE. Advances in redox-responsive drug delivery systems of tumor microenvironment. *J Nanobiotechnology.* 2018;16(1):1-10.
116. Zhang J, Ahn KS, Kim C, et al. Nimbolide-induced oxidative stress abrogates STAT3 signaling cascade and inhibits tumor growth in transgenic adenocarcinoma of mouse prostate model. *Antioxid Redox Signal.* 2016;24(11):575-589.
117. Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in tumorigenesis. *Cell Mol Life Sci.* 2020;77(22):4459-4483.
118. Kumar P, Liu B, Behl G. A comprehensive outlook of synthetic strategies and applications of redox-responsive nanogels in drug delivery. *Macromol Biosci.* 2019;19(8):1900071.
119. Chen X, Zhang Y, Tang C, et al. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. *Int J Pharm.* 2017;529(1-2):102-115.
120. Zhao W, Zhao Y, Wang Q, Liu T, Sun J, Zhang R. Remote light-responsive nanocarriers for controlled drug delivery: advances and perspectives. *Small.* 2019;15(45):1903060.
121. Colak B, Cihan MC, Ertas YN. 3D-Printed, Implantable Alginate/CuS nanoparticle scaffolds for local tumor treatment via synergistic photothermal, photodynamic, and chemodynamic therapy. *Acs Appl Nano Mater.* 2023;6:16076-16085.
122. Ertas YN, Ertas D, Erdem A, Segujja F, Dulchavsky S, Ashammakhi N. Diagnostic, therapeutic, and theranostic multifunctional microneedles. *Small.* 2024:e2308479.
123. Olejniczak J, Carling C-J, Almutairi A. Photocontrolled release using one-photon absorption of visible or NIR light. *J Control Release.* 2015;219:18-30.
124. Ding F, Gao X, Huang X, et al. Polydopamine-coated nucleic acid nanogel for siRNA-mediated low-temperature photothermal therapy. *Biomaterials.* 2020;245:119976.
125. Xie X, Yang Y, Yang Y, Mei X. Photolabile-caged peptide-conjugated liposomes for siRNA delivery. *J Drug Target.* 2015;23(9):789-799.
126. Yang Y, Yang Y, Xie X, et al. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery. *Biomaterials.* 2015;48:84-96.
127. Liu X, Madhankumar AB, Slagle-Webb B, Sheehan JM, Surguladze N, Connor JR. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. *Cancer Res.* 2011;71(6):2240-2249.
128. Yin T, Wang P, Li J, et al. Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. *Biomaterials.* 2013;34(18):4532-4543.
129. Bhavsar D, Subramanian K, Sethuraman S, Krishnan UM. 'Nano-in-nano' hybrid liposomes increase target specificity and gene silencing efficiency in breast cancer induced SCID mice. *Eur J Pharm Biopharm.* 2017;119:96-106.
130. Taetz S, Bochot A, Surace C, et al. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. *Oligonucleotides.* 2009;19(2):103-116.
131. Golkar N, Samani SM, Tamaddon AM. Data on cell growth inhibition induced by anti-VEGF siRNA delivered by Stealth liposomes incorporating G2 PAMAM-cholesterol versus Metafectene® as a function of exposure time and siRNA concentration. *Data in brief.* 2016;8:1018-1023.
132. Yonenaga N, Kenjo E, Asai T, et al. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. *J Control Release.* 2012;160(2):177-181.
133. Dakwar GR, Braeckmans K, Ceelen W, De Smedt SC, Remaut K. Exploring the HYDRATION method for loading siRNA on liposomes: the interplay between stability and biological activity in human undiluted ascites fluid. *Drug Deliv Transl Res.* 2017;7(2):241-251.
134. Li W, Yan R, Liu Y, et al. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid in vitro and in vivo. *Drug Deliv.* 2019;26(1):794-802.
135. Oh HR, Jo HY, Park JS, et al. Galactosylated liposomes for targeted co-delivery of doxorubicin/vimentin siRNA to hepatocellular carcinoma. *Nanomaterials (Basel, Switzerland).* 2016;6(8):141.
136. Yang D, Li Y, Qi Y, et al. Delivery of siRNA using cationic liposomes incorporating stearic acid-modified octa-arginine. *Anticancer Res.* 2016;36(7):3271-3276.
137. Bedi D, Musacchio T, Fagbohun OA, et al. Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes. *Nanomedicine.* 2011;7(3):315-323.
138. Guo P, Yang J, Jia D, Moses MA, Auguste DT. ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer. *Theranostics.* 2016;6(1):1-13.
139. Yang Y, Xie X, Xu X, et al. Thermal and magnetic dual-responsive liposomes with a cell-penetrating peptide-siRNA conjugate for enhanced and targeted cancer therapy. *Colloids Surf B Biointerfaces.* 2016;146:607-615.
140. Gomes-da-Silva LC, Ramalho JS, Pedrosa de Lima MC, Simões S, Moreira JN. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells. *Eur J Pharm Biopharm.* 2013;85(3):356-364. Pt A.
141. Xiang B, Dong DW, Shi NQ, et al. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. *Biomaterials.* 2013;34(28):6976-6991.
142. Al-Attar T, Madhally SV. Targeted cancer treatment using a combination of siRNA-liposomes and resveratrol-electrospun fibers in co-cultures. *Int J Pharm.* 2019;569:118599.
143. Bhunia S, Radha V, Chaudhuri A. CDC20siRNA and paclitaxel co-loaded nanometric liposomes of a nipecotic acid-derived cationic amphiphile inhibit xenografted neuroblastoma. *Nanoscale.* 2017;9(3):1201-1212.
144. Yao Y, Su Z, Liang Y, Zhang N. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery. *Int J Nanomed.* 2015;10:6185-6197.
145. Khatri N, Baradia D, Vhora I, Rath M, Misra A. cRGD grafted liposomes containing inorganic nano-precipitate complexed siRNA for intracellular delivery in cancer cells. *J Control Release.* 2014;182:45-57.
146. Li Y, Liu R, Yang J, Ma G, Zhang Z, Zhang X. Dual sensitive and temporally controlled camptothecin prodrug liposomes code-

- livery of siRNA for high efficiency tumor therapy. *Biomaterials*. 2014;35(36):9731-9745.
147. Yang T, Li B, Qi S, et al. Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo. *Theranostics*. 2014;4(11):1096-1111.
 148. Bernards R, Brummelkamp TR, Beijersbergen RL. shRNA libraries and their use in cancer genetics. *Nat Methods*. 2006;3(9):701-706.
 149. Zhang J, Ding M, Xu K, Mao L, Zheng J. shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy. *Oncotarget*. 2016;7(20):29824.
 150. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. *Proc Natl Acad Sci USA*. 2002;99(3):1443-1448.
 151. Sui G, Soohoo C, Affar EB, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc Natl Acad Sci USA*. 2002;99(8):5515-5520.
 152. El-Anead A. Current strategies in cancer gene therapy. *Eur J Pharmacol*. 2004;498(1-3):1-8.
 153. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. *Adv Drug Deliv Rev*. 2009;61(9):746-759.
 154. Seraj S, Lee J, Ahn HJ. Systemic delivery of Eg5 shRNA-expressing plasmids using PEGylated DC-Chol/DOPE cationic liposome: long-term silencing and anticancer effects in vivo. *Biochem Pharmacol*. 2019;166:192-202.
 155. Li K, Liu T, Chen J, Ni H, Li W. Survivin in breast cancer-derived exosomes activates fibroblasts by up-regulating SOD1, whose feedback promotes cancer proliferation and metastasis. *J Biol Chem*. 2020;295(40):13737-13752.
 156. Yu P, Li AX, Chen XS, et al. PKM2-c-Myc-survivin cascade regulates the cell proliferation, migration, and tamoxifen resistance in breast cancer. *Front Pharmacol*. 2020;11:550469.
 157. Li F, Shanmugam MK, Siveen KS, et al. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. *Oncotarget*. 2015;6(7):5147-5163.
 158. George R, Hehlhans S, Fleischmann M, Rodel C, Fokas E, Rodel F. Advances in nanotechnology-based platforms for survivin-targeted drug discovery. *Expert Opin Drug Dis*. 2022;17(7):733-754.
 159. Suzuki M, Ohwada M, Tamada T, Tsuru S. Thymidylate synthase activity as a prognostic factor in ovarian cancer. *Oncology*. 1994;51(4):334-338.
 160. Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K. Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis. *Oncology*. 2000;59(2):152-157.
 161. Iizuka K, Jin C, Eshima K, Hong MH, Eshima K, Fukushima M. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model. *Drug Des Dev Ther*. 2018;12:673-683.
 162. Hynynen K. Ultrasound for drug and gene delivery to the brain. *Adv Drug Deliv Rev*. 2008;60(10):1209-1217.
 163. Zhao G, Huang Q, Wang F, et al. Targeted shRNA-loaded liposome complex combined with focused ultrasound for blood brain barrier disruption and suppressing glioma growth. *Cancer Lett*. 2018;418:147-158.
 164. Xu J, Wang Y, Li Z, Wang Q, Zhou X, Wu W. Ultrasound-targeted microbubble destruction (UTMD) combined with liposome increases the effectiveness of suppressing proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) via targeting metadherin (MTDH) by ShRNA. *Med Sci Monit*. 2019;25:2640-2648.
 165. Xiao W, Zhang W, Huang H, et al. Cancer targeted gene therapy for inhibition of melanoma lung metastasis with eIF3i shRNA loaded liposomes. *Mol Pharm*. 2020;17(1):229-238.
 166. Saavedra-Alonso S, Zapata-Benavides P, Chavez-Escamilla AK, et al. WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma. *Exp Ther Med*. 2016;12(6):3778-3784.
 167. Li F, Shanmugam MK, Chen L, et al. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. *Cancer Prev Res (Phila)*. 2013;6(8):843-854.
 168. Shishodia S, Sethi G, Ahn KS, Aggarwal BB. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. *Biochem Pharmacol*. 2007;74(1):118-130.
 169. Wei W, Zarghami N, Abasi M, Ertas YN, Pilehvar Y. Implantable magnetic nanofibers with ON-OFF switchable release of curcumin for possible local hyperthermic chemotherapy of melanoma. *J Biomed Mater Res A*. 2022;110(4):851-860.
 170. Manu KA, Shanmugam MK, Li F, et al. Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. *J Mol Med*. 2014;92(3):267-276.
 171. Li X, Zhang L, Yu L, et al. shRNA-mediated AMBRA1 knock-down reduces the cisplatin-induced autophagy and sensitizes ovarian cancer cells to cisplatin. *J Toxicol Sci*. 2016;41(1):45-53.
 172. Wang P, Yu N, Wang Y, Sun H, Yang Z, Zhou S. Co-delivery of PLK1-specific shRNA and doxorubicin via core-crosslinked pH-sensitive and redox ultra-sensitive micelles for glioma therapy. *J Mater Chem B*. 2018;6(1):112-124.
 173. Templeton N. Cationic liposomes as in vivo delivery vehicles. *Curr Med Chem*. 2003;10(14):1279-1287.
 174. Tseng W-C, Haselton FR, Giorgio TD. Transfection by cationic liposomes using simultaneous single cell measurements of plasmid delivery and transgene expression. *J Biol Chem*. 1997;272(41):25641-25647.
 175. Yazdi JR, Tafaghodi M, Sadri K, et al. Folate targeted PEGylated liposomes for the oral delivery of insulin: in vitro and in vivo studies. *Colloids Surf B Biointerfaces*. 2020;194:111203.
 176. Menger FM, Littau C. Gemini-surfactants: synthesis and properties. *J Am Chem Soc*. 1991;113(4):1451-1452.
 177. Yang P, Singh J, Wettig S, Foldvari M, Verrall RE, Badea I. Enhanced gene expression in epithelial cells transfected with amino acid-substituted gemini nanoparticles. *Eur J Pharm Biopharm*. 2010;75(3):311-320.
 178. Li W, Shi J, Zhang C, et al. Co-delivery of thioredoxin 1 shRNA and doxorubicin by folate-targeted gemini surfactant-based

- cationic liposomes to sensitize hepatocellular carcinoma cells. *J Mater Chem B*. 2014;2(30):4901-4910.
179. Peng Z, Wang C, Fang E, Lu X, Wang G, Tong Q. Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy. *PLoS One*. 2014;9(3):e92924.
 180. Li N, Mai Y, Liu Q, Gou G, Yang J. Docetaxel-loaded D- α -tocopheryl polyethylene glycol-1000 succinate liposomes improve lung cancer chemotherapy and reverse multidrug resistance. *Drug Deliv Transl Res*. 2021;11(1):131-141.
 181. Guo X, Zhang J, Cai Q, et al. Acetic acid transporter-mediated, oral, multifunctional polymer liposomes for oral delivery of docetaxel. *Colloids Surf B Biointerfaces*. 2021;198:111499.
 182. Kang Y, Lu L, Lan J, et al. Redox-responsive polymeric micelles formed by conjugating gambogic acid with bioreducible poly(amido amine)s for the co-delivery of docetaxel and MMP-9 shRNA. *Acta Biomater*. 2018;68:137-153.
 183. Yuan S, Qiao T, Zhuang X, Chen W, Xing N, Zhang Q. Knockdown of the M2 isoform of pyruvate kinase (PKM2) with shRNA enhances the effect of docetaxel in human NSCLC cell lines in vitro. *Yonsei Med J*. 2016;57(6):1312-1323.
 184. Chowdhury N, Vhora I, Patel K, Doddapaneni R, Mondal A, Singh M. Liposomes co-loaded with 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) shRNA plasmid and docetaxel for the treatment of non-small cell lung cancer. *Pharm Res*. 2017;34(11):2371-2384.
 185. Tian H, Liu S, Zhang J, et al. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin. *J Biomed Nanotechnol*. 2012;8(4):633-641.
 186. Chen H, Fan X, Zhao Y, et al. Stimuli-responsive polysaccharide enveloped liposome for targeting and penetrating delivery of survivin-shRNA into breast tumor. *ACS Appl Mater Interfaces*. 2020;12(19):22074-22087.
 187. Swami R, Kumar Y, Chaudhari D, et al. pH sensitive liposomes assisted specific and improved breast cancer therapy using co-delivery of SIRT1 shRNA and Docetaxel. *Mater Sci Eng C Mater Biol Appl*. 2021;120:111664.
 188. Chen Z, Liang K, Liu J, et al. Enhancement of survivin gene downregulation and cell apoptosis by a novel combination: liposome microbubbles and ultrasound exposure. *Med Oncol*. 2009;26(4):491-500.
 189. Chauhan N, Dhasmana A, Jaggi M, Chauhan SC, Yallapu MM. Mir-205: a potential biomedicine for cancer therapy. *Cells*. 2020;9(9):1957.
 190. Plantamura I, Cataldo A, Cosentino G, Iorio MV. miR-205 in Breast Cancer: state of the Art. *Int J Mol Sci*. 2021;22(1):27.
 191. Zhou C, Zhao X, Duan S. The role of miR-543 in human cancerous and noncancerous diseases. *J Cell Physiol*. 2021;236(1):15-26.
 192. Naghizadeh S, Mohammadi A, Duijf PH, et al. The role of miR-34 in cancer drug resistance. *J Cell Physiol*. 2020;235(10):6424-6440.
 193. Ha M, Kim VN. Regulation of microRNA biogenesis. *Nat Rev Mol Cell Biol*. 2014;15(8):509-524.
 194. Mirzaei S, Zarrabi A, Asnaf SE, et al. The role of microRNA-338-3p in cancer: growth, invasion, chemoresistance, and mediators. *Life Sci*. 2021;268:119005.
 195. Paskeh MDA, Mirzaei S, Orouei S, et al. Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers based on pre-clinical and clinical evidence. *Int J Biol Macromol*. 2021;191:727-737.
 196. Yu Z, Guo J, Hu M, Gao Y, Huang L. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma. *ACS Nano*. 2020;14(4):4816-4828.
 197. Cui X, Zhou D, Du Q, et al. MicroRNA200a enhances antitumor effects in combination with doxorubicin in hepatocellular carcinoma. *Transl Oncol*. 2020;13(10):100805.
 198. Xue H, Yu Z, Liu Y, et al. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma. *Int J Nanomed*. 2017;12:5271-5287.
 199. Fan YP, Liao JZ, Lu YQ, et al. MiR-375 and doxorubicin co-delivered by liposomes for combination therapy of hepatocellular carcinoma. *Mol Ther Nucleic Acids*. 2017;7:181-189.
 200. He H, Tian W, Chen H, Deng Y. MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1. *Mol Med Rep*. 2016;13(2):1923-1929.
 201. Xu F, Liao JZ, Xiang GY, et al. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma. *Cancer Med*. 2017;6(3):651-661.
 202. Dai X, Wang L, Deivasigamni A, et al. A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. *Oncotarget*. 2017;8(8):12831-12842.
 203. Ledezma-Gallegos F, Jurado R, Mir R, Medina LA, Mondragon-Fuentes L, Garcia-Lopez P. Liposomes co-encapsulating cisplatin/mifepristone improve the effect on cervical cancer: in vitro and in vivo assessment. *Pharmaceutics*. 2020;12(9):897.
 204. Dana P, Bunthot S, Suktham K, et al. Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer. *Colloids Surf B Biointerfaces*. 2020;196:111270.
 205. Wang L, Liang TT. CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells. *AMB Expr*. 2020;10(1):54.
 206. Ippoliti R, Lendaro E, D'Agostino I, et al. A chimeric saporin-transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity. *FASEB J*. 1995;9(12):1220-1225.
 207. Li X, Ding L, Xu Y, Wang Y, Ping Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. *Int J Pharm*. 2009;373(1-2):116-123.
 208. Sakurai K, Sohda T, Ueda S, et al. Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue. *Hepatogastroenterology*. 2014;61(130):426-430.
 209. Zhang W, Peng F, Zhou T, et al. Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes. *Int J Nanomed*. 2015;10:4825-4836.
 210. Ruttala HB, Chitrapriya N, Kaliraj K, et al. Facile construction of bioreducible crosslinked polypeptide micelles for enhanced cancer combination therapy. *Acta Biomater*. 2017;63:135-149.
 211. Jan N, Madni A, Khan S, et al. Biomimetic cell membrane-coated poly (lactic-co-glycolic acid) nanoparticles for biomedical applications. *Bioeng Transl Med*. 2022;8:e10441.

212. Jing C, Yan L, Wei Z, et al. Exogenous delivery of microRNA-134 (miR-134) using α -tocopherol-based PEGylated liposome for effective treatment in skin squamous cell carcinoma. *Drug Deliv Transl Res*. 2020;11(3):1000-1008.
213. Sharma S, Rajendran V, Kulshreshtha R, Ghosh PC. Enhanced efficacy of anti-miR-191 delivery through stearylamine liposome formulation for the treatment of breast cancer cells. *Int J Pharm*. 2017;530(1-2):387-400.
214. Gao J, Sun J, Li H, et al. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. *Biomaterials*. 2010;31(9):2655-2664.
215. Ling K, Jiang H, Li Y, Tao X, Qiu C, Li F-R. A self-assembling RNA aptamer-based graphene oxide sensor for the turn-on detection of theophylline in serum. *Biosens Bioelectron*. 2016;86:8-13.
216. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. *Proc Natl Acad Sci USA*. 1979;76(3):1438-1442.
217. Lund K, Bostad M, Skarpen E, et al. The novel EpCAM-targeting monoclonal antibody 3-17I linked to saporin is highly cytotoxic after photochemical internalization in breast, pancreas and colon cancer cell lines. *MAbs*. 2014;6:1038-1050.
218. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. *Hum Pathol*. 2004;35(1):122-128.
219. Zhao Y, Xu J, Le VM, et al. EpCAM aptamer-functionalized cationic liposome-based nanoparticles loaded with miR-139-5p for targeted therapy in colorectal cancer. *Mol Pharm*. 2019;16(11):4696-4710.
220. Jiang L, Wang H, Chen S. Aptamer (AS1411)-Conjugated liposome for enhanced therapeutic efficacy of miRNA-29b in ovarian cancer. *J Nanosci Nanotechnol*. 2020;20(4):2025-2031.
221. Tao J, Ding WF, Che XH, et al. Optimization of a cationic liposome-based gene delivery system for the application of miR-145 in anticancer therapeutics. *Int J Mol Med*. 2016;37(5):1345-1354.
222. Huang F, Zhao F, Liang LP, et al. Optimizing transfection efficiency of cervical cancer cells transfected by cationic liposomes lipofectamineTM2000. *Asian Pac J Cancer Prev*. 2015;16(17):7749-7754.
223. Xu B, Mei J, Ji W, et al. LncRNA SNHG3, a potential oncogene in human cancers. *Cancer Cell Int*. 2020;20(1):1-11.
224. Shen C, Yang C, Xia B, You M. Long non-coding RNAs: emerging regulators for chemo/immunotherapy resistance in cancer stem cells. *Cancer Lett*. 2021;500:244-252.
225. Wu M, Zhang X, Han X, Pandey V, Lobie PE, Zhu T. The potential of long noncoding RNAs for precision medicine in human cancer. *Cancer Lett*. 2020;501:12-19.
226. Robless EE, Howard JA, Casari I, Falasca M. Exosomal long non-coding RNAs in the diagnosis and oncogenesis of pancreatic cancer. *Cancer Lett*. 2021;501:55-65.
227. Ma Z, Wang YY, Xin HW, et al. The expanding roles of long non-coding RNAs in the regulation of cancer stem cells. *Int J Biochem Cell Biol*. 2019;108:17-20.
228. Cheng JT, Wang L, Wang H, et al. Insights into biological role of LncRNAs in epithelial-mesenchymal transition. *Cells*. 2019;8(10):1178.
229. Kansara S, Pandey V, Lobie PE, Sethi G, Garg M, Pandey AK. Mechanistic involvement of long non-coding RNAs in oncotherapeutics resistance in triple-negative breast cancer. *Cells*. 2020;9(6):1511.
230. Pandya G, Kirtonia A, Sethi G, Pandey AK, Garg M. The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential. *Biochim Biophys Acta Rev Cancer*. 2020;1874(2):188423.
231. Gala K, Khattar E. Long non-coding RNAs at work on telomeres: functions and implications in cancer therapy. *Cancer Lett*. 2021;502:120-132.
232. Bhardwaj V, Tan YQ, Wu MM, et al. Long non-coding RNAs in recurrent ovarian cancer: theranostic perspectives. *Cancer Lett*. 2021;502:97-107.
233. Lim YWS, Xiang X, Garg M, et al. The double-edged sword of H19 lncRNA: insights into cancer therapy. *Cancer Lett*. 2020;500:253-262.
234. Ashrafizadeh S, Ashrafizadeh M, Zarrabi A, et al. Long non-coding RNA in the doxorubicin resistance of cancer cells. *Cancer Lett*. 2021;508:104-114.
235. Ye H, Chu X, Cao Z, et al. A novel targeted therapy system for cervical cancer: co-delivery system of antisense LncRNA of MDC1 and oxaliplatin magnetic thermosensitive cationic liposome drug carrier. *Int J Nanomed*. 2021;16:1051-1066.
236. Yu W, Qiao Y, Tang X, et al. Tumor suppressor long non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to inhibit FoxA1 in liver cancer cells. *Cell Signal*. 2014;26(12):2961-2968.
237. Gai C, Liu C, Wu X, et al. MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells. *Cell Death Dis*. 2020;11(9):751.
238. Yu Q, Qiu Y, Wang X, et al. Efficient siRNA transfer to knockdown a placenta specific lncRNA using RGD-modified nano-liposome: a new preeclampsia-like mouse model. *Int J Pharm*. 2018;546(1-2):115-124.
239. Song X, Liu C, Wang N, et al. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. *Adv Drug Deliv Rev*. 2021;168:158-180.
240. Liu D, Zhao X, Tang A, et al. CRISPR screen in mechanism and target discovery for cancer immunotherapy. *Biochim Biophys Acta Rev Cancer*. 2020;1874(1):188378-188378.
241. Xing H, Meng L-H. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment. *Acta Pharmacol Sin*. 2020;41(5):583-587.
242. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337(6096):816-821.
243. O'Connell MR, Oakes BL, Sternberg SH, East-Seletsky A, Kaplan M, Doudna JA. Programmable RNA recognition and cleavage by CRISPR/Cas9. *Nature*. 2014;516(7530):263-266.
244. Garneau JE, Dupuis M-È, Villion M, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. *Nature*. 2010;468(7320):67-71.
245. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc Natl Acad Sci USA*. 2012;109(39):E2579-E2586.

246. Hale CR, Zhao P, Olson S, et al. RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. *Cell*. 2009;139(5):945-956.
247. Hazafa A, Mumtaz M, Farooq MF, et al. CRISPR/Cas9: a powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. *Life Sci*. 2020;263:118525.
248. Zhang W, Liu Y, Zhou X, Zhao R, Wang H. Applications of CRISPR-Cas9 in gynecological cancer research. *Clin Genet*. 2020;97(6):827-834.
249. Sharma G, Sharma AR, Bhattacharya M, Lee SS, Chakraborty C. CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. *Mol Ther*. 2021;29(2):571-586.
250. Liu Z, Liao Z, Chen Y, Zhou L, Huangting W, Xiao H. Research on CRISPR/system in major cancers and its potential in cancer treatments. *Clin Transl Oncol*. 2021;23(3):425-433.
251. Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. *Cell*. 2020;181(1):136-150.
252. Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. *Nat Nanotechnol*. 2020;15(4):313-320.
253. Xu CF, Chen GJ, Luo YL, et al. Rational designs of in vivo CRISPR-Cas delivery systems. *Adv Drug Deliv Rev*. 2021;168:3-29.
254. Schuh RS, Poletto É, Fachel FNS, Matte U, Baldo G, Teixeira HF. Physicochemical properties of cationic nanoemulsions and liposomes obtained by microfluidization complexed with a single plasmid or along with an oligonucleotide: implications for CRISPR/Cas technology. *J Colloid Interface Sci*. 2018;530:243-255.
255. Aksoy YA, Yang B, Chen W, et al. Spatial and temporal control of CRISPR-Cas9-mediated gene editing delivered via a light-triggered liposome system. *ACS Appl Mater Interfaces*. 2020;12(47):52433-52444.
256. Zhen S, Liu Y, Lu J, et al. Human papillomavirus onco-gene manipulation using clustered regularly interspersed short palindromic repeats/Cas9 delivered by pH-sensitive cationic liposomes. *Hum Gene Ther*. 2020;31(5-6):309-324.
257. Zuris JA, Thompson DB, Shu Y, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. *Nat Biotechnol*. 2015;33(1):73-80.
258. Sun W, Ji W, Hall JM, et al. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. *Angew Chem Int Ed Engl*. 2015;54(41):12029-12033.
259. Kouranova E, Forbes K, Zhao G, et al. CRISPRs for optimal targeting: delivery of CRISPR components as DNA, RNA, and protein into cultured cells and single-cell embryos. *Hum Gene Ther*. 2016;27(6):464-475.
260. Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. *Clin Cancer Res*. 2007;13(6):1663-1674.
261. Zhou J, Atsina K-B, Himes BT, Strohbehn GW, Saltzman WM. Novel delivery strategies for glioblastoma. *Cancer J (Sudbury, Mass)*. 2012;18(1):89-99.
262. Chen Z, Liu F, Chen Y, et al. Targeted delivery of CRISPR/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles. *Adv Funct Mater*. 2017;27(46):1703036.
263. Montaudon E, Nikitorowicz-Buniak J, Sourd L, et al. PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. *Nat Commun*. 2020;11(1):4053.
264. Su S, Chhabra G, Ndiaye MA, et al. PLK1 and NOTCH positively correlate in melanoma and their combined inhibition results in synergistic modulations of key melanoma pathways. *Mol Cancer Ther*. 2021;20(1):161-172.
265. Zhen S, Takahashi Y, Narita S, Yang YC, Li X. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome. *Oncotarget*. 2017;8(6):9375-9387.
266. Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. *Int J Clin Oncol*. 2020;25(5):818-830.
267. Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. *Nat Immunol*. 2020;21(11):1346-1358.
268. Chen X, Pan X, Zhang W, et al. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. *Acta Pharm Sin B*. 2020;10(5):723-733.
269. Nakazawa T, Natsume A, Nishimura F, et al. Effect of CRISPR/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth. *Cells*. 2020;9(4):998.
270. Luo B, Zhan Y, Luo M, et al. Engineering of α -PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration. *Cell Death Dis*. 2020;11(11):973.
271. Lu S, Yang N, He J, et al. Generation of cancer-specific cytotoxic PD-1(-) T cells using liposome-encapsulated CRISPR/Cas system with dendritic/tumor fusion cells. *J Biomed Nanotechnol*. 2019;15(3):593-601.
272. Jubair L, Lam AK, Fallaha S, McMillan NAJ. CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice. *PLoS One*. 2021;16(1):e0223288.
273. Zhdanov VP. Intracellular RNA delivery by lipid nanoparticles: diffusion, degradation, and release. *Biosystems*. 2019;185:104032.
274. Zelphati O, Szoka Jr FC. Mechanism of oligonucleotide release from cationic liposomes. *Proc Natl Acad Sci USA*. 1996;93(21):11493-11498.
275. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. *Chem Rev*. 2016;116(4):2602-2663.
276. Schäfer J, Höbel S, Bakowsky U, Aigner A. Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. *Biomaterials*. 2010;31(26):6892-6900.
277. Yang T, Bantegui T, Pike K, Bloom R, Phipps R, Bai S. In vitro evaluation of optimized liposomes for delivery of small interfering RNA. *J Liposome Res*. 2014;24(4):270-279.
278. Hattori Y, Nakamura M, Takeuchi N, et al. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex. *J Drug Target*. 2019;27(2):217-227.
279. Zhang L, Liu S, Liu H, et al. Versatile cationic liposomes for RIP3 overexpression in colon cancer therapy and RIP3

- downregulation in acute pancreatitis therapy. *J Drug Target*. 2020;28(6):627-642.
280. Hashemi M, Ghadyani F, Hasani S, et al. Nanoliposomes for doxorubicin delivery: reversing drug resistance, stimuli-responsive carriers and clinical translation. *J Drug Deliv Sci Technol*. 2023;80:104112.
 281. Majzoub RN, Chan C-L, Ewert KK, et al. Uptake and transfection efficiency of PEGylated cationic liposome–DNA complexes with and without RGD-tagging. *Biomaterials*. 2014;35(18):4996-5005.
 282. Pattipeiluhu R, Crielard S, Klein-Schiphorst I, Florea BI, Kros A, Campbell F. Unbiased identification of the liposome protein corona using photoaffinity-based chemoproteomics. *ACS Cent Sci*. 2020;6(4):535-545.
 283. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. *Chem Soc Rev*. 2012;41(7):2780-2799.
 284. Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. *Nat Mater*. 2009;8(7):543-557.
 285. Caracciolo GJN. Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona. *Nanoscale*. 2018;10(9):4167-4172.
 286. Barrán-Berdón AL, Pozzi D, Caracciolo G, et al. Time evolution of nanoparticle–protein corona in human plasma: relevance for targeted drug delivery. *Langmuir*. 2013;29(21):6485-6494.
 287. Zhu Y, Meng Y, Zhao Y, et al. Toxicological exploration of peptide-based cationic liposomes in siRNA delivery. *Colloids Surf B*. 2019;179:66-76.
 288. Zhang Y, Chu B, Fan Q, Song X, Xu Q, Qu Y. M2-type macrophage-targeted delivery of IKK β siRNA induces M2-to-M1 repolarization for CNV gene therapy. *Nanomed Nanotechnol Biol Med*. 2024;57:102740.
 289. Qin B, Jiang M, Li X, et al. Oxygen nanocarrier broke the hypoxia trap of solid tumors and rescued transfection efficiency for gene therapy. *J Nanobiotechnol*. 2021;19:1-14.
 290. Arora S, Layek B, Singh J. Design and validation of liposomal ApoE2 gene delivery system to evade blood–brain barrier for effective treatment of Alzheimer's disease. *Mol Pharm*. 2020;18(2):714-725.

How to cite this article: Yildiz SN, Entezari M, Paskeh MDA, et al. Nanoliposomes as nonviral vectors in cancer gene therapy. *MedComm*. 2024;5:e583. <https://doi.org/10.1002/mco2.583>